
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **October 4, 2018**

EMERGENT BIOSOLUTIONS INC.

(Exact name of registrant as specified in its charter)

DELAWARE
(State or other jurisdiction
of incorporation)

001-33137
(Commission File Number)

14-1902018
(IRS Employer
Identification No.)

400 Professional Drive, Suite 400,
Gaithersburg, Maryland 20879
(Address of principal executive offices, including zip code)

(240) 631-3200
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Explanatory Note

This Form 8-K/A is filed as an amendment (“Amendment No. 1”) to the Current Report on Form 8-K filed by Emergent BioSolutions Inc. (“Emergent”) on October 5, 2018 (the “Initial 8-K”). As previously reported in the Initial 8-K, on October 4, 2018, pursuant to the Agreement and Plan of Merger (the “Merger Agreement”) by and among Emergent, PaxVax Holding Company Ltd., an exempted company incorporated with limited liability in the Cayman Islands (“PaxVax”(1)), Panama Merger Sub, Ltd., an exempted company incorporated with limited liability in the Cayman Islands and an indirect wholly-owned subsidiary of Emergent (“Merger Sub”), and PaxVax SH Representative LLC, a limited liability company organized under the laws of the Cayman Islands (the “PaxVax Shareholder Representative”), Emergent completed the acquisition of PaxVax via merger, whereby Merger Sub was merged with and into PaxVax and PaxVax continued as the surviving company (the “PaxVax Merger”). In addition, on October 15, 2018, pursuant to the share purchase agreement, dated August 28, 2018 (the “Share Purchase Agreement”), by and among Emergent, Adapt Pharma Limited, an Irish private company limited by shares (“Adapt”), the shareholders of Adapt identified in the Share Purchase Agreement and Seamus Mulligan, an individual, as the Sellers’ representative, Emergent completed the previously announced purchase of all of the issued and outstanding ordinary shares of Adapt from the Sellers (the “Adapt Acquisition”).

This Amendment No. 1 is being filed to include the historical financial statements of PaxVax, as required by Item 9.01(a) of Form 8-K and the pro forma financial information required by Item 9.01(b) of Form 8-K, which information was excluded from the Initial 8-K in reliance upon Item 9.01(a)(4) and Item 9.01(b)(2) of Form 8-K. Because the closing of the PaxVax Merger and Adapt Acquisition occurred close in time, the proforma financial information includes combined financial information of Emergent, PaxVax and Adapt.

Item 9.01 Financial Statements and Exhibits.

(a) Financial Statements of Businesses Acquired.

The unaudited condensed consolidated interim financial statements of PaxVax Global, L.P. as of June 30, 2018 and for the six months ended June 30, 2018 and 2017 and accompanying notes are included in Exhibit 99.2 hereto and are incorporated herein by reference.

The audited consolidated financial statements of PaxVax Global, L.P. as of and for the year ended December 31, 2017 and accompanying notes are included in Exhibit 99.3 hereto and are incorporated herein by reference.

(b) Pro Forma Financial Information.

The unaudited pro forma condensed combined financial information of Emergent, PaxVax and Adapt for the year ended December 31, 2017 and for the six months ended June 30, 2018, including the notes related thereto, are filed as Exhibit 99.4 hereto and incorporated herein by reference.

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
2	<u>Merger Agreement, dated August 8, 2018, among Emergent, PaxVax, Merger Sub and the PaxVax Shareholder Representative*, **†</u>
23	<u>Consent of Moss Adams LLP, independent auditors for PaxVax Global, L.P.</u>
99.1	<u>Press Release, dated October 4, 2018.†</u>
99.2	<u>Unaudited condensed consolidated financial statements of PaxVax Global, L.P. as of June 30, 2018 and for the six months ended June 30, 2018 and 2017 and accompanying notes thereto.</u>
99.3	<u>Audited consolidated financial statements of PaxVax Global, L.P. as of and for the year ended December 31, 2017 and accompanying notes thereto.</u>
99.4	<u>Unaudited pro forma condensed combined financial information of Emergent, PaxVax and Adapt as of June 30, 2018 and for the year ended December 31, 2017 and for the six months ended June 30, 2018 and accompanying notes thereto.</u>

(1) Prior to the completion of the PaxVax Merger, but after June 30, 2018, PaxVax Global, L.P. contributed all of its subsidiaries, operations, assets and liabilities to a newly-formed entity, PaxVax Holding Company Ltd. Therefore, PaxVax Global, L.P. and PaxVax Holding Company Ltd are collectively referred to herein as “PaxVax” and the historical financial information of PaxVax Global, L.P. has been used to prepare the unaudited pro forma condensed combined financial information statements attached hereto as well as satisfy the requirements per Regulation S-X Rule 3-05.

† Previously filed.

* Confidential treatment has been requested for certain portions of this exhibit. The confidential portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission. In addition, schedules and exhibits to the Merger Agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. Emergent hereby undertakes to furnish supplementally copies of any of the omitted schedules and/or exhibits upon request by the U.S. Securities and Exchange Commission; provided, however, that Emergent may request confidential treatment for any schedule and/or exhibit so furnished.

** Disclosure schedules have been omitted. A copy of any omitted schedule or exhibit will be furnished to the Securities and Exchange Commission upon request.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EMERGENT BIOSOLUTIONS INC.

Dated: December 12, 2018

By: /s/ RICHARD S. LINDAHL

Name: Richard S. Lindahl

Title: Executive Vice President, Chief Financial Officer and Treasurer

Consent of Independent Auditors

We consent to the incorporation by reference in the following Registration Statements of Emergent Biosolutions Inc. of our report dated May 7, 2018, relating to the 2017 consolidated financial statements of PaxVax Global, L.P. and subsidiaries (the “Company”), which report expresses an unqualified opinion and includes an emphasis of matter paragraph regarding the Company’s ability to continue as a going concern, appearing in the Amendment No. 1 to the Current Report on Form 8-K (No. 001-33137) of Emergent BioSolutions Inc. dated December 12, 2018:

- Registration Statement on Form S-8 (No. 333-139190) pertaining to the Employee Stock Option Plan, as amended and restated, the 2006 Stock Incentive Plan and individual director options agreements of Emergent BioSolutions Inc.,
- Registration Statement on Form S-8 (No. 333-161154) pertaining to the Amended and Restated 2006 Stock Incentive Plan of Emergent BioSolutions Inc.,
- Registration Statement Form S-4 (No. 333-169351) of Emergent BioSolutions Inc. and Subsidiaries,
- Registration Statement Form S-3 (No. 333-181133) of Emergent BioSolutions Inc. and Subsidiaries,
- Registration Statement Form S-8 (No. 333-184699) pertaining to the 2012 Employee Stock Purchase Plan and the Second Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan,
- Registration Statement Form S-8 (No. 333-196232) pertaining to the Third Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan,
- Registration Statement Form S-8 (No. 333-216294) pertaining to the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan,
- Registration Statement Form S-8 (No. 333-225283) pertaining to the Fifth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, and
- Registration Statement Form S-3 (No. 333-226544) of Emergent BioSolutions Inc. and Subsidiaries.

/s/ Moss Adams LLP

San Francisco, California
December 12, 2018

Condensed Consolidated Financial Statements

PaxVax Global, L.P. and Subsidiaries
For the Six Months Ended
June 30, 2018 and 2017
(Unaudited)

CONTENTS

	<u>PAGE</u>
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	
Condensed Consolidated Balance Sheets (Unaudited)	3
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)	4
Condensed Consolidated Statement of Partnership Interests (Unaudited)	5
Condensed Consolidated Statements of Cash Flows (Unaudited)	6
Condensed Notes to Consolidated Financial Statements (Unaudited)	7

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
June 30, 2018 and December 31, 2017
(Unaudited, amounts in thousands)

	June 30, 2018	December 31, 2017
Assets		
Current assets:		
Cash and cash equivalents	\$ 8,545	\$ 30,059
Accounts receivable, net	7,867	2,506
Inventories	16,601	17,617
Prepaid expenses and other current assets	3,702	3,019
Total current assets	36,715	53,201
Property, plant, and equipment, net	39,704	38,606
Restricted cash	72,126	82,624
Intangible assets, net	2,895	2,985
Deferred tax assets	905	1,085
Other long-term assets	661	851
Total assets	<u>\$ 153,006</u>	<u>\$ 179,352</u>
Liabilities and partnership interests		
Current liabilities:		
Accounts payable	\$ 5,216	\$ 6,196
Accrued expenses	14,044	11,789
Other current liabilities	1,271	1,048
Total current liabilities	20,531	19,033
Convertible unsecured loans	16,394	12,091
Related party convertible notes payable	7,109	7,090
Pension plan obligation	10,723	11,481
Other long term liabilities	193	358
Total liabilities	54,950	50,053
Partnership interests:		
Contributed capital	102,251	134,131
Accumulated other comprehensive loss	(4,195)	(4,832)
Total partnership interests	98,056	129,299
Total liabilities and partnership interests	<u>\$ 153,006</u>	<u>\$ 179,352</u>

See accompanying notes

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited, amounts in thousands)

	Six Months Ended June 30,	
	2018	2017
Revenues:		
Net product revenue	\$ 21,327	\$ 17,288
Grant and contract revenue	1,854	2,390
Other revenue	124	—
Total net revenues	<u>23,305</u>	<u>19,678</u>
Costs and expenses:		
Cost of revenues	12,054	8,495
Research and development	19,669	14,072
General and administrative	9,533	7,625
Sales and marketing	9,246	7,386
Total costs and expenses	<u>50,502</u>	<u>37,578</u>
Loss from operations	(27,197)	(17,900)
Interest and other income (expense), net:		
Change in fair value of convertible unsecured loans	(4,303)	305
Gain on extinguishment of royalty obligation	—	616
Interest income, net	735	1,122
Other income/(expense), net	(901)	1,524
Total interest and other income (expense), net	<u>(4,469)</u>	<u>3,567</u>
Net loss before income taxes	(31,666)	(14,333)
Income tax (expense) benefit	(374)	175
Net loss	<u>\$ (32,040)</u>	<u>\$ (14,158)</u>
Statements of comprehensive loss		
Net loss	\$ (32,040)	\$ (14,158)
Other comprehensive income (loss):		
Unrealized gain (loss) on pension plan obligation	(662)	913
Foreign currency translation adjustment	37	(280)
Unrealized loss on investments	(12)	(89)
	<u>(637)</u>	<u>544</u>
Comprehensive loss	<u>\$ (32,677)</u>	<u>\$ (13,614)</u>

See accompanying notes

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF PARTNERSHIP INTERESTS
(Unaudited, amounts in thousands)

	Contributed Capital	Accumulated Other Comprehensive Loss	Total Partnership Interests
Balance at December 31, 2017	\$ 134,131	\$ (4,832)	\$ 129,299
Stock-based compensation expense	160	—	160
Unrealized loss on pension plan	—	662	662
Unrealized gain on foreign currency translation	—	(37)	(37)
Unrealized loss on investments	—	12	12
Net loss	(32,040)	—	(32,040)
Balance at June 30, 2018	<u>\$ 102,251</u>	<u>\$ (4,195)</u>	<u>\$ 98,056</u>

See accompanying notes

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, amounts in thousands)

	Six Months Ended June 30,	
	2018	2017
Cash flows from operating activities		
Net loss	\$ (32,040)	\$ (14,158)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	2,308	2,158
Amortization of premium on investment securities	—	458
Pension plan expenses	608	926
Pension plan contributions	(427)	(467)
Deferred income taxes	70	(273)
Stock-based compensation	160	200
Change in fair value of convertible unsecured loans	4,303	(305)
Gain from extinguishment of royalty obligation	—	(616)
Other	43	—
Changes in operating assets and liabilities:		
Accounts receivable	(5,366)	(266)
Prepaid expenses and other assets	(493)	262
Inventory	1,016	(3,555)
Income taxes	181	41
Accounts payable	(1,389)	(3,315)
Accrued expenses and other current liabilities	1,504	(2,865)
Net cash used in operating activities	(29,522)	(21,775)
Cash flows from investing activities		
Sale of marketable securities	—	65,546
Purchases of property, plant, and equipment	(2,738)	(6,187)
Net cash (used in) provided by investing activities	(2,738)	59,359
Cash flows from financing activities		
Payments on capital lease obligations	(25)	(19)
Repayment of notes payable	—	(3,500)
Payment for capital distribution	—	(121,252)
Payment of retention fund for partnership interests	—	(1,050)
Net cash used in financing activities	(25)	(125,821)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	273	(872)
Net decrease in cash, cash equivalents and restricted cash	(32,012)	(89,109)
Cash, cash equivalents and restricted cash, beginning of period (1)	112,683	215,267
Cash, cash equivalents and restricted cash, end of period (1)	\$ 80,671	\$ 126,158
Supplemental cash flow information		
Cash paid for taxes	\$ 104	\$ 41
Supplemental disclosure non-cash financing activities		
Equipment acquired through capital lease	\$ 12	\$ —
Purchases of equipment in accounts payable	\$ 1,178	\$ 767

(1) See Note 2 for the schedule of cash, cash equivalents and restricted cash

See accompanying notes

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

PaxVax Global, L.P. and its subsidiaries (PaxVax Global, L.P., PaxVax, or the Company) primarily focus on the development and commercialization of specialty vaccines for the overlooked traveler segment. The Company is headquartered in Redwood City, California, USA, and maintains research and development and Current Good Manufacturing Practice (CGMP) facilities in San Diego, California, USA, and in Thörishaus, Switzerland. The Company sells and distributes vaccines in the United States, United Kingdom, Italy, Spain and Switzerland. The Company is also in the business of marketing and selling priority review vouchers (PRV) we may obtain by developing new drug and biological products for the prevention and treatment of certain tropical diseases which qualify for U.S. Food and Drug Administration (FDA) PRV status. In 2016, the Company obtained its first priority review voucher from the U.S. FDA upon approval of its application for a biological license for Vaxchora, a Cholera vaccine. The voucher was sold during 2016 for \$290.0 million to a third party. The Company uses the list of U.S. FDA qualified PRV eligible tropical diseases as a basis for defining its portfolio of research and development projects.

The Company's commercial portfolio includes Vivotif, a Typhoid vaccine, and Vaxchora, a vaccine for Cholera. The Company began recognizing net product revenues from sales of Vaxchora and related cost of sales in 2016. The Company also distributes Dukoral and Ixiaro for Valneva Austria GMBH in Italy, Spain, and Portugal as well as Measles and Diphtheria for Sanofi in Switzerland. The clinical-stage product portfolio includes a licensed vaccine for chikungunya that is currently in phase 2 trials, adenovirus strains 4 and 7, and adenovirus-based vaccines for pandemic H5N1 influenza, and HIV all of which have included phase 1 clinical trials. The Company's proprietary adenoviral-based technology platform is intended to provide a platform technology for the rapid development of oral vaccines that can target both viral and bacterial antigens, and to be suitable for use in both developed and developing countries. In addition, the Company has preclinical vaccine candidates for the mosquito-borne Zika virus.

PaxVax, Inc. was incorporated in Delaware in 2006 and commenced operations in 2007. On December 3, 2015, PaxVax, Inc. effected a recapitalization in which a newly formed company, PaxVax Global, L.P., became its parent holding company of the worldwide consolidated subsidiaries. Simultaneous with this transaction, existing investors of PaxVax, Inc. became the sole owners of PaxVax Global, L.P. through a newly formed company, 2015 Shareholder Holding Company Limited (Holding Company). Holding Company and PaxVax Global G.P. (the general partner of PaxVax Global, L.P. and controlled by Holding Company) were the original sole owners of PaxVax Global, L.P. On December 4, 2015, Cerberus PaxVax, L.P. (Cerberus PaxVax), an affiliate of Cerberus Capital Management, L.P. (Cerberus) acquired a 70% interest in PaxVax Global, L.P. for a net cash amount of \$102.0 million (the Cerberus Transaction). Concurrent with the acquisition, Holding Company also transferred its interests in and control of PaxVax Global G.P. to Cerberus PaxVax Global GP Holdings, Ltd., an affiliate of Cerberus. The Holding Company holds the remaining 30% interest in the Company, (together referred to as the Partnership).

Basis of presentation and principles of consolidation - The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP), and include the accounts of PaxVax Global, L.P. and its wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been omitted from the condensed consolidated financial statements. The Company believes that these condensed consolidated financial statements include all necessary and recurring adjustments for the fair presentation of the interim period results. The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2017.

Accounts receivable, unbilled receivables and allowance for doubtful accounts - As of June 30, 2018 and December 31, 2017, trade receivables from product sales was \$7.4 million and \$1.9 million, respectively. Research contracts receivables were \$1.1 million as of June 30, 2018 of which \$0.5 million was recorded as accounts receivable and \$0.6 million as earned but unbilled revenue included in prepaid expenses and current other assets. Research contracts receivables were \$1.2 million as of December 31, 2017 of which \$0.7 million was recorded as accounts receivable and \$0.5 million as earned but unbilled revenue included in prepaid expenses and current other assets. As

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

of June 30, 2018, three customers accounted for 20%, 17% and 14% of total accounts receivable from product sales and two customers accounted for 62% and 38% of total accounts receivable from research contracts. As of December 31, 2017, one customer accounted for 23% of total accounts receivable from product sales and one customer accounted for 96% of total accounts receivable from research contracts.

The allowance for doubtful accounts is based on the Company's assessment of the collectability of its customer accounts. As of June 30, 2018 and December 31, 2017, the allowance for doubtful accounts was \$88,000 and \$83,000, respectively.

Identifiable intangible assets - Acquired intangible assets are amortized over their useful lives and are comprised of developed technology of \$2.5 million and trade name of \$1.1 million. The weighted-average remaining useful life of the intangible assets as of June 30, 2018 is 16 years.

Intangible assets subject to amortization as of June 30, 2018 and December 31, 2017 were as follows (in thousands):

	June 30, 2018		
	Gross Carrying Amount	Accumulated Amortization	Net Book Value
Developed technology	\$ 2,500	\$ (490)	\$ 2,010
Trade name	1,100	(215)	885
Total	<u>\$ 3,600</u>	<u>\$ (705)</u>	<u>\$ 2,895</u>

	December 31, 2017		
	Gross Carrying Amount	Accumulated Amortization	Net Book Value
Developed technology	\$ 2,500	\$ (427)	\$ 2,073
Trade name	1,100	(188)	912
Total	<u>\$ 3,600</u>	<u>\$ (615)</u>	<u>\$ 2,985</u>

The Company recorded amortization expense of \$90,000 included in general and administrative expenses during each of the six months ended June 30, 2018 and 2017. As of June 30, 2018, the Company expects to record amortization expense in future periods as follows (in thousands):

Period Ending December 31:	
2018 (remaining 6 months)	\$ 90
2019	180
2020	180
2021	180
2022	180
Thereafter	2,085
Total expected amortization expense	<u>\$ 2,895</u>

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

Concentration of Revenue - During the six months ended June 30, 2018, \$16.2 million or 70% of total net revenues accounted for total domestic revenue from product revenue, and grant and contract revenue and \$7.1 million or 30% of total net revenues accounted for total international revenue from product revenue and royalty income. During the six months ended of June 30, 2017, \$14.3 million or 73% of total net revenues accounted for total domestic from product revenue, and grant and contract revenue and \$5.4 million or 27% of total net revenues accounted for total international revenue from product revenue.

During the six months ended June 30, 2018, the Company recognized revenue from three significant customers which amounted to 13%, 12%, and 10% of total revenues, and during the six months ended June 30, 2017, the Company recognized revenue from the three customers, of which two of the three are the same, which amounted to 13%, 19%, and 11% of total revenues.

Inventories — Inventories as of June 30, 2018 and December 31, 2017 are comprised of the following (in thousands):

	June 30, 2018	December 31, 2017
Work in process	\$ 10,355	\$ 12,983
Raw materials	974	1,258
Finished goods	5,272	3,376
	<u>\$ 16,601</u>	<u>\$ 17,617</u>

Recent Accounting Pronouncements Not Yet Adopted

In July 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (“ASU”) No. 2018-11, Leases. Targeted Improvements (“ASU 2018-11”). In issuing ASU 2018-11, the FASB decided to provide another transition method in addition to the existing transition method by allowing entities to initially apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating the impact that ASU 2016-02 and ASU 2018-11 will have on its condensed consolidated financial statements.

In February 2018, the FASB issued ASU No. 2018-02, Income Statement — Reporting Comprehensive Income. Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, that gives entities the option to reclassify to retained earnings tax effects related to items that have been stranded in accumulated other comprehensive income as a result of the Tax Cuts and Jobs Act (the Act). An entity that elects to reclassify these amounts must reclassify stranded tax effects related to the Act’s change in U.S. federal tax rate for all items accounted for in other comprehensive income. These entities can also elect to reclassify other stranded effects that relate to the Act but do not directly relate to the change in the federal rate. Entities can choose whether to apply the amendments retrospectively to each period in which the effect of the Act is recognized or to apply the amendments in the period of adoption. The standard is effective for the Company on January 1, 2019, with early adoption permitted. The Company is evaluating the impact of adopting this new accounting guidance on its condensed consolidated financial statements.

In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments. ASU No. 2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments in the statement of cash flows by adding or clarifying guidance on eight specific cash flow issues. ASU No. 2016-15 is effective for fiscal years beginning after December 15, 2017, and for interim periods within that fiscal year. The new accounting pronouncement is not expected to have a significant impact on the its condensed consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), and additional ASUs subsequently during 2018, which requires lessees to recognize a liability associated with obligations to make payments under the terms of the arrangement in addition to a right-of-use asset representing the lessee’s right to use, or control the use of the given asset assumed under the lease. The standard will be effective for the Company in 2020. Early adoption is permitted. The Company is currently evaluating this new standard and the impact it will have on its condensed consolidated financial statements.

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

In May 2014, the FASB issued ASU 2014-09, Revenues from Contracts with Customers (Topic 606). Since May 2014, additional ASUs have been issued that addresses certain implementation issues that have surfaced since the issuance of ASU No. 2014-09. This guidance applies to any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards. The core principle of this guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance supersedes existing revenue recognition guidance, including most industry-specific guidance, as well as certain related guidance on accounting for contract costs. In July 2015, FASB deferred the adoption dates of this standard whereby the standard becomes effective for the Company in 2019. Early adoption is permitted for nonpublic entities. An entity should apply the guidance using one of two methods: retrospectively to each prior reporting period presented with practical expedients or retrospectively with the cumulative effect of initial adoption of the guidance recognized at the date of initial application. The Company is currently evaluating the impact of adopting this standard on its condensed consolidated financial statements and disclosures.

There are no other recently issued accounting pronouncements that are expected to have a material impact on the Company's financial position, results of operations or cash flows.

NOTE 2 — BALANCE SHEET COMPONENTS

Property, Plant, and Equipment

Property, plant, and equipment consist of the following as of June 30, 2018 and December 31, 2017 (in thousands):

	June 30, 2018	December 31, 2017
Laboratory and production machinery	\$ 22,670	\$ 21,582
Buildings	14,610	14,337
Land	906	921
Leasehold improvements	4,174	4,175
Computer equipment and software	4,320	4,103
Furniture and fixtures	630	574
Property, plant, and equipment, gross	47,310	45,692
Less accumulated depreciation and amortization	(19,218)	(17,290)
Property, plant, and equipment, net	28,092	28,402
Construction in process	11,612	10,204
	<u>\$ 39,704</u>	<u>\$ 38,606</u>

Depreciation and amortization expense was \$2.2 million and \$2.1 million for the six months ended June 30, 2018 and 2017, respectively. Amortization of capitalized software is included in depreciation and amortization expense, which is expensed over a two to five year period. Amortization of capitalized software for each of the six months ended June 30, 2018 and 2017 was \$0.3 million.

Equipment purchased under capital leases was \$12,000 during the six months ended June 30, 2018 and none during the six months ended 2017.

Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the statement balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows as of June 30, 2018 and December 31, 2017:

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

	June 30, 2018	December 31, 2017
Cash and cash equivalents	\$ 8,545	\$ 30,059
Restricted cash	72,126	82,624
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows	<u>\$ 80,671</u>	<u>\$ 112,683</u>

Accrued Liabilities

Accrued liabilities as of June 30, 2018 and December 31, 2017 consisted of the following (in thousands):

	June 30, 2018	December 31, 2017
Accrued compensation and benefits	\$ 6,441	\$ 6,870
Sales returns and sales-related accruals	3,132	1,970
Clinical trial related accruals	1,869	424
Professional services	235	910
Other accruals	2,367	1,615
	<u>\$ 14,044</u>	<u>\$ 11,789</u>

NOTE 3 - FAIR VALUE MEASUREMENT

The accounting guidance for fair value states that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value, as follows:

Level 1— Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 — Directly or indirectly observable inputs other than in Level 1 that include quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active.

Level 3 — Unobservable inputs that are supported by little or no market activity that reflect the reporting entity's own assumptions about the assumptions that market participants would use in pricing the asset or liability.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

The Company estimate the fair values of its corporate debt securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker or dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; prepayment or default projections based on historical data; and other observable inputs.

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

The following table summarizes the assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):

	June 30, 2018			
	Level 1	Level 2	Level 3	Total
Assets:				
Money market funds	\$ 71,936	\$ —	\$ —	\$ 71,936
Cash	8,735	—	—	8,735
Total	<u>\$ 80,671</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 80,671</u>
Liabilities:				
Convertible unsecured loans	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 16,394</u>	<u>\$ 16,394</u>

	December 31, 2017			
	Level 1	Level 2	Level 3	Total
Assets:				
Money market funds	\$ 73,578	\$ —	\$ —	\$ 73,578
Corporate debt securities(1)	—	15,011	—	15,011
Cash	24,094	—	—	24,094
Total	<u>\$ 97,672</u>	<u>\$ 15,011</u>	<u>\$ —</u>	<u>\$ 112,683</u>
Liabilities:				
Convertible unsecured loans	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 12,091</u>	<u>\$ 12,091</u>

(1) Corporate debt securities is classified as restricted cash on the consolidated balance sheets for the year ending December 31, 2017.

There were no transfers between Level1, Level 2 and Level 3 during the periods presented.

Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table is a summary of available-for-sale securities (in thousands):

	June 30, 2018		
	Amortized Cost	Gross Unrealized Losses	Estimated Fair Value
Money market funds	\$ 71,936	\$ —	\$ 71,936
Total	<u>\$ 71,936</u>	<u>\$ —</u>	<u>\$ 71,936</u>

	December 31, 2017		
	Amortized Cost	Gross Unrealized Losses	Estimated Fair Value
Money market funds	\$ 73,578	\$ —	\$ 73,578
Corporate debt securities (1)	15,023	(12)	15,011
Total	<u>\$ 88,601</u>	<u>\$ (12)</u>	<u>\$ 88,589</u>

(1) The available-for-sales securities have been in a continuous unrealized loss position for less than 12 months.

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

The following table presents the contractual maturities of available-for-sale securities as of December 31, 2017 (in thousands):

	December 31, 2017	
	Amortized Cost	Estimated Fair Value
Due in one year or less	\$ 15,023	\$ 15,011

Based on the Company's review of its available-for-sale securities, the Company believes there were no other-than-temporary impairments on these securities as of December 31, 2017. The Company does not intend to sell these securities nor believes that it will be required to sell these securities before the recovery of their amortized cost. Gross realized gains and gross realized losses were immaterial for the year ended December 31, 2017.

As of June 30, 2018 and December 31, 2017, financial instruments measured using Level 3 inputs on a recurring basis consisted of convertible unsecured loans where the Company has elected the fair value option to account for these financial instruments.

The Company estimates the fair value of the convertible unsecured loans using a discounted cash flow model based on the probability of a Winding-Up Event, as defined, amount and timing of expected payouts and an assumed discount rate. The Company will continue to adjust the liability for changes in fair value until the earlier of the repayment of the principal and interest of the loans, or a Winding-Up Event occurs. On August 8, 2018, the Company entered into an agreement and plan of merger with Emergent BioSolutions Inc. As a result of this Winding-Up Event, the Company recognized a the fair value adjustment for the six months ending June 30, 2018 to approximate the Company's assessment of the present-value of estimated future repayment amount. See also Convertible Unsecured Loans at Note 6, Debt Financing, and Note 11, Subsequent Events.

Activity for the fair value of the convertible unsecured loans using significant unobservable inputs (level 3) is presented in the table below (in thousands):

Balance at December 31, 2017	\$ 12,091
Adjustment to fair value included in earnings	4,303
Balance at June 30, 2018	<u>\$ 16,394</u>

NOTE 4 —COMPREHENSIVE LOSS

Comprehensive loss is comprised of net loss and other comprehensive income (loss). As of June 30, 2018 and December 31, 2017, other accumulated comprehensive loss is comprised of unrealized losses on the Company's pension plan for its employees in Switzerland, a net unrealized loss on investments, and the impact of foreign currency translation.

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

The following table summarizes the changes in accumulated other comprehensive loss by component (in thousands):

	Pension Liability	Foreign Currency Translation	Investments in Marketable Securities	Total
As of December 31, 2016	\$ (3,075)	\$ (522)	\$ (159)	\$ (3,756)
Unrealized gains (losses) arising during the period	(913)	280	89	(544)
As of June 30, 2017	<u>\$ (3,988)</u>	<u>\$ (242)</u>	<u>\$ (70)</u>	<u>\$ (4,300)</u>
	Pension Liability	Foreign Currency Translation	Investments in Marketable Securities	Total
As of December 31, 2017	\$ (4,646)	\$ (174)	\$ (12)	\$ (4,832)
Unrealized gains (losses) arising during the period	662	(37)	12	637
As of June 30, 2018	<u>\$ (3,984)</u>	<u>\$ (211)</u>	<u>\$ —</u>	<u>\$ (4,195)</u>

The effect of income taxes for the six months ended June 30, 2018 and 2017 on these balances is immaterial.

NOTE 5 - COMMITMENTS AND CONTINGENCIES

Operating Leases — The Company's office and manufacturing facilities located in San Diego and Redwood City, California, are subject to noncancelable operating lease agreements. The Company provided aggregate cash deposits of \$0.2 million as security for the operating leases, as of June 30, 2018 and December 31, 2017. The cash deposits related to property leases were recorded in prepaid expenses and other current assets and other long-term assets within the Company's consolidated balance sheet.

Included within the lease agreements are tenant improvement allowances totaling approximately \$0.4 million. The Company is amortizing the portion of the deferred rent liability related to the tenant improvement allowances as a reduction to rent expense over the remaining term of the lease.

The Company's leases contain rent escalation clauses. Rent expense is recorded on a straight-line basis over the term of the leases. The difference between the base rent payment and the straight-line rent amount is recorded as a deferred rent liability. As of June 30, 2018 and December 31, 2017, the Company has deferred rent liabilities of approximately \$0.1 million included in other current liabilities and \$0.1 million included in other long term liabilities in the consolidated balance sheet. Rent expense, including common area charges, was \$0.9 million and \$0.7 million for the six months ending June 30, 2018 and 2017, respectively.

Future minimum commitments under the lease agreements as of June 30, 2018 are as follows (in thousands):

Period Ending December 31:	
2018 (remaining 6 months)	\$ 813
2019	1,137
2020	618
2021	564
2022	58
Thereafter	3
Total minimum lease payments	<u>\$ 3,193</u>

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

Licensing Agreements - The Company has entered into licensing agreements with certain parties, whereby the Company has been granted exclusive and nonexclusive licenses to certain patented technology and know-how of certain additional proprietary technology. In addition to licensing fees, the agreements obligate the Company to pay royalties to the Licensors on certain milestones and revenue generated from the Company's use of the licensed patents and technology, including product sales revenue and proceeds from sublicensing agreements.

The agreements typically terminate on the last to expire patent right associated with the related agreement. The agreements obligate the Company to make annual licensing payments until expiration. For the six months ending June 30, 2018 and 2017, amounts due and recognized for licensing, royalty, and patent reimbursement fees were insignificant.

NOTE 6 - DEBT FINANCING

A summary of debt outstanding at June 30, 2018 and December 31, 2017 is as follows (in thousands):

	June 30, 2018		
	Current	Long Term	Total
Related party convertible notes payable	\$ —	\$ 7,109	\$ 7,109
Convertible unsecured loans	—	16,394	16,394
	<u>\$ —</u>	<u>\$ 23,503</u>	<u>\$ 23,503</u>
	December 31, 2017		
	Current	Long Term	Total
Related party convertible notes payable	\$ —	\$ 7,090	\$ 7,090
Convertible unsecured loans	—	12,091	12,091
	<u>\$ —</u>	<u>\$ 19,181</u>	<u>\$ 19,181</u>

Related Party Convertible Notes Payable

In September 2015, the Company executed convertible promissory notes and received \$7.0 million in net cash proceeds from an investment fund that held two of five of the Company's Board of Director seats and a controlling voting interest in the Company at that time. The terms of the notes bear interest at 0.56% per annum.

In December 2015, the terms of the \$7.0 million convertible promissory note were amended. All outstanding principal and all accrued but unpaid interest under the note is due and payable upon demand at any time on or after the occurrence of: a winding up and/or dissolution of the partnership; a sale or exclusive license of all or substantially all of the assets of the partnership or its subsidiaries to an unrelated third party; a merger, acquisition, or sale of partnership interests; in which the partners immediately prior to such event have received consideration for no less than half of the value of their partnership interests, or upon default. In the event Cerberus or its affiliate proposes to make an additional investment into the partnership, the note may also be converted into common limited partnership interests of PaxVax Global, L.P., in accordance with, and subject to, certain terms and provisions. The amendment to the convertible promissory notes was considered to be a modification and accounted for prospectively as it did not result in a significant change in their fair value.

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

Convertible Unsecured Loans

In June 2008, the Company received strategic award funding in the amount of \$12.8 million (First Award). In June 2010, the Company received a second strategic award funding in the amount of \$3.0 million (Second Award). These awards are from a charitable foundation trust, The Wellcome Trust Limited (Wellcome Trust), in the form of convertible unsecured loans (Loans) related to certain research and development programs. As of June 30, 2018 and December 31, 2017, the Company had outstanding borrowings of \$15.8 million in total from both awards.

The Loans initially accrued interest at 2.00% above the NatWest Bank plc base rate. At Wellcome Trust's discretion, it could require the Company to convert some or all of the respective Loans into the next round of financing offered by the Company at the earlier of certain events or upon an event of default. The strategic award with Wellcome Trust also did not allow them to require the Company to repay the award if such repayment would have caused doubts as to the Company's ability to continue as a going concern.

On December 4, 2015, the Master Amendment Deed (the Deed) was signed by and among PaxVax Inc., The Wellcome Trust Limited, and PaxVax Global, L.P., which amended the original agreement and stated that, effective upon the Deed, Wellcome Trust shall not demand conversion of each Loan and demand repayment of any Loan (or part thereof) or accrued interest. The only automatic conversion will occur upon a Winding-Up Event, as defined in the deed, such as a dissolution, sale, merger, acquisition, recapitalization or reorganization of the partnership or a material breach of the Company's obligations under the Funding Agreement. In the Deed, all parties agreed that, upon the occurrence of a Winding-Up Event after the effective date of the Deed, only the principal amounts of both First and Second Awards will be converted to common limited partnership interests of PaxVax Global, L.P., and all accrued interest under each award shall be extinguished. As of December 4, 2015, the date of the Deed, the accrued interest that has not been recorded was \$2.9 million. Thus the Deed released the Company's liability to any accrued interest.

The Company elected to apply the fair value option to account for the Loans. As of June 30, 2018 and December 31, 2017, the Company is in compliance with its covenant obligations under the Funding Agreement.

As the Company has elected the fair value option to account for the Loans, the change in fair value was recorded as part of the fair value adjustment in the consolidated statements of operations for the six years months ended June 30, 2018 and year ended December 31, 2017.

The carrying value of the Loans at June 30, 2018 is as follows (in thousands):

	First Award	Second Award	Total
Principal amount of award	\$ 12,765	\$ 2,999	\$ 15,764
Cumulative change in fair value	510	120	630
Total carrying value	\$ 13,275	\$ 3,119	\$ 16,394

The carrying value of the Loans at December 31, 2017 is as follows (in thousands):

	First Award	Second Award	Total
Principal amount of award	\$ 12,765	\$ 2,999	\$ 15,764
Cumulative change in fair value	(2,974)	(699)	(3,673)
Total carrying value	\$ 9,791	\$ 2,300	\$ 12,091

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

Royalty Obligation Payable

In July 2014, the Company executed a secured loan and security agreement with a previous third-party lender for an available loan amount of up to \$50.0 million in three tranches subject to certain requirements at the date of funding. In December 2015, the Company terminated all commitments under the loan agreement, except for payment of future royalties (royalty obligation payable), by repaying the obligations and liabilities under the agreement which comprised full repayment of the outstanding principal and accrued interest of the then-outstanding debt and certain prepayment penalties and fees.

The Royalty Obligation Payable contains repayment terms of future royalties estimated by the Company at \$2.9 million as of December 31, 2015. These future royalties are computed at 3% of the Company's revenues earned and payable to the lender in three yearly payments beginning on September 15, 2017. The Company records the net present value of the estimated expected future royalty payments as a liability, and accretes interest expense based on the future payment dates. A new effective interest rate is computed when the estimated future payments change, and the carrying amount of the royalty obligation payable liability is adjusted as if the new effective interest rate had been used since inception. Interest expense is recognized at the new effective rate beginning in the period in which the change in estimate occurs.

As of December 31, 2016, the royalty repayment amount of \$4.1 million represents the estimated fair value of future royalties, and is presented as current and noncurrent royalty obligation payable in the Consolidated Balance Sheets. In June 2017, the royalty obligation payable was settled for \$3.5 million. The extinguishment of royalty obligation resulted in a gain of \$0.6 million, which the Company recognized in the consolidated statements of operations in the six months ended June 30, 2017.

NOTE 7 - FOUNDERS' UNITS

PaxVax Founders' Incentive Unit Plan

On December 4, 2015, Holding Company established the PaxVax Founders' Incentive Unit Plan (PFIUP). Under the PFIUP, 50,000,000 units were reserved for grant of which 30,180,412 units were subsequently awarded to certain holders of outstanding awards in the PaxVax, Inc.'s 2007 Equity Incentive Plan (the Plan) which was terminated in 2015. These shares are known as modification units because they qualify for modification treatment of share based payments under US GAAP.

As of June 30, 2018 and December 31, 2017, 48,610,107 and 48,352,549 units had been awarded, respectively. As of June 30, 2018 and December 31, 2017, 40,223,194 and 36,663,495 PFIUP units were fully vested, respectively. As of June 30, 2018 and December 31, 2017, there were 8,386,914 and 11,689,054 PFIUP unvested units outstanding, respectively. The remaining units vest over various terms up to 48 months and are divided between shares subject to modification accounting treatment and Top-Up (issued) units not subject to modification treatment. All PFIUP units automatically vest upon a Liquidity Event which is defined as a winding up, dissolution, sale of all assets, merger or similar corporate event of PaxVax Global, L.P. or IPO of PaxVax Global, L.P. or PaxVax, Inc. Participants who hold vested Incentive Units at the time of any other dividend or distribution to holders of common stock of Holding Company or at the time of a Liquidity Event will be entitled to a cash payment. The Company recognizes compensation expense for the original grant date fair value of the modified shares over the remaining vesting period. The Company did not recognize any compensation expense related to the PFIUP Top-Up (issued) units for the six months ended June 30, 2018 and 2017 because the occurrence of the performance condition required for payment associated with these awards did not occur and therefore there is no fair value associated with these units.

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

The following represents the PFIUP activity for the period ended June 30, 2018 and December 31, 2017:

	Units Available for Issuance	Unvested Units Outstanding		
		Total	Modification units	Top-Up (issued) units
Balance at December 31, 2017	1,647,451	11,689,054	1,840,080	9,848,974
Issued	(450,000)	450,000	—	450,000
Vested	—	(3,559,699)	(1,072,688)	(2,487,011)
Forfeited	192,441	(192,441)	(1,716)	(190,725)
Balance at June 30, 2018	1,389,892	8,386,914	765,676	7,621,238

NOTE 8 - PARTNERSHIP INTERESTS

Partnership Interests

Under the Amended and Restated Exempted Limited Partnership Agreement of PaxVax Global, L.P. (the Partnership Agreement) dated December 4, 2015, the Company is authorized to issue up to 10,000,000 partnership interests. The number of preferred and common interests are authorized as the Board determines from time to time. The Partnership Agreement provides for three classes of partnership interests; the “Common Interests”, the “Preferred Interests” and the “Profits Interests” of which 2,550,000 are Common Interests, 5,950,000 are Preferred Interests and 1,500,000 are Profits Interests. The Profits Interests are equally divided into two series, 750,000 the “Series A Profits Interests” and 750,000 “Series B Profits Interests”. The number of preferred and common units are authorized as the Board determines from time to time. There were 1,173,500 Profits Interests Issued and Outstanding and 326,500 Profits Interests available for issuance as of June 30, 2018 and December 31, 2017. The partners’ liability under the Partnership Agreement is limited to their undistributed capital contributions.

The general partner of the Company is PaxVax Global G.P. Limited (General Partner). Holding Company and Cerberus PaxVax are the Company’s limited partners. The limited partners do not have a right to vote on any matter except required by law. The Profits Interests do not have any voting rights under any circumstances.

Priority of Distributions

The General Partner may in its discretion make distributions from time to time pursuant to the distribution priorities as set forth in the Partnership Agreement. All distributions, other than tax distributions (as provided per the Partnership Agreement) shall be made to partnership interests holders in respect of their outstanding partnership interests only in the following order and priority:

Ordinary course distributions - First, to the Cerberus PaxVax equal to any uninsured losses associated with the Cerberus Acquisition as of the date of the distribution. Second, to the limited partners pro rata in proportion to their respective number of Preferred Interests and Common Interests. Third, to the holders of vested Series A Profits Interests pro rata in proportion to their respective number of Preferred Interests, Common Interests and vested Series A Profits Interests until an aggregate amount of no less than \$300.0 million has been distributed to the Preferred Interests, Common Interests and Series A Profits Interests holders subject to the Preferred Interests and Common Interest holders first receiving distributions of no less than \$150.0 million. Fourth, to the holders of the Preferred Interests, Common Interests, vested Series A Profits Interests and vested Series B Profits Interests on a pro rata in proportion to their respective number of Preferred Interests, Common Interests, vested Series A Profits Interests and vested Series B Profits Interests.

Distributions following the receipt of PRV proceeds - Net PRV proceeds when received will be distributed first to Cerberus PaxVax equal to any uninsured losses associated with the Cerberus Acquisition as of the date of the distribution. Second, to Cerberus PaxVax equal to any advances it has made to partners of the Company. Third, to the holders of Preferred Interests and Common Interests on a pro rata

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

basis of their ownership until an aggregate of no less than \$150.0 million has been distributed. Fourth to the Preferred Interests, Common Interests and vested Series A Profits Interests, pro rata in proportion to their respective number of Preferred Interests, Common Interests and vested Series A Profits Interests until no less than \$175.0 million has been distributed. Fifth, to the Preferred Interests, Common Interests and vested Series A Profits Interests holders pro rata in proportion to their respective number of Preferred Interests, Common Interests and Series A Profits Interests until no less than \$300.0 million has been distributed. The distribution is made pro rata to vested Series A Profits Interests on a fully diluted basis assuming all Common, Preferred, and vested Series A Profits Interests are outstanding with the remaining balance split equally between the Common and Preferred interest holders. Distributions thereafter are made to the Preferred Interests, Common Interests and vested Series A Profits Interests and vested Series B Profits Interests on a pro rata basis with respect to the outstanding and vested interests with the amount going to the Preferred Interests and Common interests also split equally. Certain amounts of the distributions made to the Common Interest holders are to be put into an escrow account to be applied against future investments in the Company.

Distributions upon a winding-up event - Following a winding up event, defined as a winding-up of the Company, sale or licensing or all the assets of the Company or its subsidiaries, a merger or acquisition or sale of the Company or a recapitalization or reorganization, whereby the Company receives proceeds from a financing for the purposes of distributing such proceeds to the partnership, the proceeds from the event will be distributed first to Cerberus PaxVax equal to any uninsured losses associated with the Cerberus Acquisition as of the date of the distribution. Second, to Cerberus PaxVax equal to any advances it has made to partners of the Company. Third, if the aggregate amount that has been previously distributed to the Preferred Interests holders is less than \$105.0 million plus all accrued but unpaid Preferred Interest holder dividends (the Liquidation Preference), the pari passu amount amongst the Preferred Interests holders until the Liquidation Preference has been met; however, if the Preferred Interest holders would receive more than the Liquidation Preference by participating on a pro rata basis in distributions on an equal basis as the Common Interests holder then the Preferred Interest holder will be treated as a Common Interests holder for purposes of the distribution. Forth, to the Common Interest Holders and vested Series A Profits Interest holder on a pro rata basis in proportion to their respective number of Common Interest and vested Series A Profits Interest up to \$300.0 million. Fifth, and thereafter, to the Common Interest and vested Series A and B Profits Interests on a pro rata basis in proportion to their held Common Interest and vested Series A and B Profits Interests.

Allocation of Profits and Losses of the Partnership

Profits or losses for any calendar year are allocated among the partners of the Company in such a manner that, as of the end of such calendar year, with respect to each partner of the Company, the sum of (i) the capital account of such partner, (ii) such partner's share of partnership minimum gain and (iii) such partner's partner nonrecourse debt minimum gain shall, as nearly as possible, be equal to the net amount, positive or negative, that would be distributed to such partner of the Company or for which such partner of the Company would be liable to the Company.

Dividends

The capital contribution associated with the Preferred Interests of the Company accrues a dividend of 8% cumulative and compounded quarterly in arrears, when and if declared.

Transfers

No limited partner is allowed to transfer, offer or agree to transfer all or any parts of any interest in such partnership interests without the prior written consent of the General Partner. All General Partner approved interests transfers are subject to compliance with the terms of the Partnership Agreement.

Dissolution and Liquidation

The Company shall dissolve upon the earlier of: (i) approval of the General Partner or (ii) upon the removal, bankruptcy or withdrawal of the General Partner if a substitute cannot be implemented or (iii) upon the final distribution of all the assets and satisfaction of all liabilities of

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

the Company. On dissolution of the Company, the General Partner shall act as liquidator or may appoint one or more representatives or interests holders as liquidator. The liquidator shall sell any portion of the Company's assets and make final distributions.

On January 24, 2017, the Partnership Agreement was amended primarily to revise clauses relating to the distribution of proceeds from the sale of PaxVax Bermuda's priority review voucher (PRV) issued in connection with the approval of Vaxchora. PaxVax Bermuda distributed to the Company \$122.2 million relating to PRV proceeds. In turn, the Company made distributions to its partners as follows: \$121.3 million was distributed to Cerberus PaxVax and \$0.9 million was distributed to Series A Profits Interests holders. Further distributions to the Company by PaxVax Bermuda, and in turn, by the Company to the Limited Partners holding Series A Profits Interests, of up to \$2.9 million were made and will be made in a series of quarterly installments from March 31, 2017 to December 31, 2019, as the Series A Profits Interests vest. For each of the six months ended June 30, 2018 and 2017, \$0.5 million had been reflected as bonus or board member fees and included in the Company's consolidated statements of operations. PaxVax Bermuda retained \$82.6 million from PRV proceeds in lieu of distributing such amount to the Company for distribution to the Holding Company. These funds will be used by the Holding Company to purchase additional equity in the Company if there is a future investment opportunity in the Company. If there is no new investment opportunity, the Holding Company will receive a distribution equal to this amount in preference to any distribution to Cerberus PaxVax or holders of Profits Interests. During the six months ended June 30, 2018, restricted cash of \$10.7 million was released from the Holding Company to the Company for use in operations.

PaxVax Profits Interests Plan

On December 4, 2015, the Company established the PaxVax Global, L.P. Profits Interests Plan (PPIP). Under the PPIP, each participant is granted the number of profits interests set forth in the award agreement. Profits interests are subject to vesting; for which 6.25% shall vest upon each calendar quarter end date after grant date. Participants in the PPIP have the right to share in distributions of the Company as set forth in the PPIP and the Company's Partnership Agreement. Upon termination of employment of the participant with the Company or its affiliate, the Company has the right, but not the obligation, to purchase the vested portion of the participant's profits interests. The number of profit interests that are reserved for issuance under the PPIP represent 15% of the outstanding equity of PaxVax Global, L.P. of which and 13% is reserved for issuance to PaxVax management and Board of Directors as of June 30, 2018 and December 31, 2017. Awards of profits interest are not considered to be a substantive class of partnership ownership and are therefore accounted for as a profit sharing arrangement. There were no liabilities outstanding relating to this plan as of each balance sheet dates. Bonus expense recognized under this plan was \$0.4 million for each of the six-months ended June 30, 2018 and 2017.

NOTE 9 - INCOME TAXES

During the six months ended June 30, 2018 and 2017, the provision for income taxes reflected on the condensed consolidated statements of operations reflect an effective rate of negative 1.18% and a negative 0.82%, respectively. During the six months ended June 30, 2018, because of the United States and Switzerland losses that are subject to full valuation allowance, those jurisdictions are not able to realize the income tax benefit of those losses. The Company also has activity in foreign jurisdictions which is subject to a lower tax rate than the United States Federal statutory tax rate. Finally, the Company has losses in pass-through entities that are not subject to income tax. As a result, for the six months ended June 30, 2018 and 2017, the Company's effective tax rate is less than the United States Federal statutory tax rate, or 34% and 21%, respectively.

In December of 2017, the Securities and Exchange Commission staff issued State Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act ("SAB 118"), which allows the Company to record provisional amounts during a measurement period not to extend beyond one year from the enactment date. Because the Tax Act was enacted in the December 2017 and ongoing guidance and accounting interpretations are expected over the next 12 months, the analysis required to record the provisional amounts for the accounting of deferred tax re-measurements and other items, such as cost recovery and state tax considerations, may be revised causing adjustments to these provisions. The Company expects to complete the analysis and update the provisional amounts within the measurement period in accordance with SAB 118.

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

NOTE 10 - DEFINED BENEFIT AND EMPLOYEE BENEFIT PLANS

Defined Benefit Plan

The Company sponsors a defined benefit pension plan (the Pension Plan) covering eligible Swiss employees. Other non-US, and non-Swiss employees are covered by government-sponsored programs and the cost to the Company is not significant. The Pension Plan is overseen by a board that is responsible for the overall administration of the Pension Plan.

The cost of providing the benefits is determined in accordance with the provisions of ASC 715 Compensation -Retirement Benefits. As of June 30, 2018 and December 31, 2017, the Pension Plan assets comprised of an insurance contract. The contract value is presumed to be its fair value based on the practicability exception in ASC 715.

Defined Contribution Plan

The Company has a 401(k) plan for all full-time employees in the United States. Employees may elect to contribute a portion of their pretax salary, not to exceed the annual limitation designated by the Internal Revenue Service, to the 401(k) plan during the year. The Company matches 4% of employee salary up to \$4,000. Matching contributions were \$0.4 million and \$0.3 million for the six months ended June 30, 2018 and 2017, respectively

NOTE 11 - SUBSEQUENT EVENTS

In August 2018, the Company contributed its interests in all of its direct subsidiaries to a newly formed entity, PaxVax Holding Company Ltd. (“Holdings”), which subsequently entered into a merger agreement with Emergent BioSolutions Inc. (“Emergent”) and one of its wholly owned subsidiaries (the “Emergent Subsidiary”) in an all-cash transaction. Upon the closing of the merger in October 2018, the Emergent Subsidiary merged with and into Holdings, with Holdings surviving the merger as a wholly-owned indirect subsidiary of Emergent, and an affiliated entity received a cash payment of \$270.0 million, exclusive of customary closing adjustments, of which \$1.0 million is held in escrow. All outstanding debt was repaid in connection with the transaction.

The Company evaluates events occurring subsequent to June 30, 2018 and recognizes such events that are material in the consolidated financial statements. In the preparation of the accompanying consolidated financial statements, the Company has evaluated subsequent events through December 12, 2018, the date the consolidated financial statements were issued.

Report of Independent Auditors and
Consolidated Financial Statements

PaxVax Global, L.P. and Subsidiaries
As of and for the Year Ended
December 31, 2017

CONTENTS

	<u>PAGE</u>
REPORT OF INDEPENDENT AUDITORS	1
CONSOLIDATED FINANCIAL STATEMENTS	
Consolidated Balance Sheet	4
Consolidated Statement of Operations and Comprehensive Loss	5
Consolidated Statement of Partnership Interests	6
Consolidated Statement of Cash Flows	7
Notes to Consolidated Financial Statements	8

REPORT OF INDEPENDENT AUDITORS

The Board of Directors
PaxVax Global, L.P. and Subsidiaries

Report on the Financial Statements

We have audited the accompanying consolidated financial statements of PaxVax Global, L.P., and its subsidiaries, which comprise the consolidated balance sheet as of December 31, 2017, and the related consolidated statements of operations and comprehensive income (loss), partnership interests, and cash flows for the year then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of PaxVax Global, L.P., and its subsidiaries as of December 31, 2017, and the consolidated results of their operations and their cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America

Emphasis of Matter

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company's recurring losses from operations and its need for additional capital raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

/s/ Moss Adams LLP

San Francisco, California
May 7, 2018

CONSOLIDATED FINANCIAL STATEMENTS

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEET

(Amounts in thousands)

	December 31, 2017
Assets	
Current assets:	
Cash and cash equivalents	\$ 30,059
Accounts receivable, net	2,506
Inventories	17,617
Prepaid expenses and other current assets	3,019
Short-term investments	—
Total current assets	<u>53,201</u>
Property, plant, and equipment, net	38,606
Restricted cash	82,624
Intangible assets, net	2,985
Long-term investments	—
Deferred tax assets	1,085
Other long-term assets	851
Total assets	<u><u>\$ 179,352</u></u>
Liabilities and partnership interests	
Current liabilities:	
Accounts payable	\$ 6,196
Accrued expenses	11,789
Current portion of royalty obligation payable	—
Other current liabilities	1,048
Total current liabilities	<u>19,033</u>
Convertible unsecured loans	12,091
Related party convertible notes payable	7,090
Royalty obligation payable, net of current portion	—
Pension plan obligation	11,481
Other long term liabilities	358
Total liabilities	<u>50,053</u>
Partnership interests:	
Contributed capital	134,131
Accumulated other comprehensive loss	(4,832)
Total partnership interests	<u>129,299</u>
Total liabilities and partnership interests	<u><u>\$ 179,352</u></u>

See accompanying notes

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS

(Amounts in thousands)

	Year Ended December 31, 2017
Revenues:	
Net product revenue	\$ 35,341
Grant and contract revenue	4,213
Total net revenues	<u>39,554</u>
Costs and expenses:	
Cost of revenues	19,773
Research and development	31,466
General and administrative	15,984
Sales and marketing	15,151
Total costs and expenses	<u>82,374</u>
Loss from operations	(42,820)
Interest and other income, net:	
Change in fair value of convertible unsecured loans	610
Gain on extinguishment of royalty obligation	616
Interest income, net	1,984
Other income, net	789
Total interest and other income, net	<u>3,999</u>
Net loss before income taxes	(38,821)
Income tax benefit	432
Net loss	<u><u>\$ (38,389)</u></u>
Statement of comprehensive loss	
Net loss	\$ (38,389)
Other comprehensive loss:	
Unrealized loss on pension plan obligation	(1,571)
Foreign currency translation adjustment	348
Unrealized gain on investments	147
	<u>(1,076)</u>
Comprehensive loss	<u><u>\$ (39,465)</u></u>

See accompanying notes

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF PARTNERSHIP INTERESTS

(Amounts in thousands)

	Contributed Capital	Accumulated Other Comprehensive Loss	Total Partnership Interests
Balance at December 31, 2016	\$ 294,441	\$ (3,756)	\$ 290,685
Capital distribution	(121,253)	—	(121,253)
Payment of retention fund for partnership interests	(1,050)	—	(1,050)
Stock-based compensation expense	382	—	382
Unrealized loss on pension plan	—	(1,571)	(1,571)
Unrealized gain on foreign currency translation	—	348	348
Unrealized gain on investments	—	147	147
Net loss	(38,389)	—	(38,389)
Balance at December 31, 2017	\$ 134,131	\$ (4,832)	\$ 129,299

See accompanying notes

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF CASH FLOWS

(Amounts in thousands)

	Year Ended December 31, 2017
Cash flows from operating activities	
Net loss	\$ (38,389)
Adjustments to reconcile net loss to net cash used in operating activities:	
Depreciation and amortization	4,289
Amortization of premium on investment securities	685
Pension plan expenses	1,745
Pension plan contributions	(934)
Stock-based compensation	382
Change in fair value of convertible unsecured loans	(610)
Gain from extinguishment of royalty obligation	(616)
Other	44
Changes in operating assets and liabilities:	
Accounts receivable	4,524
Prepaid expenses and other assets	1,577
Inventory	(916)
Deferred tax assets	(723)
Accounts payable	(192)
Accrued expenses and other current liabilities	(1,237)
Net cash used in operating activities	(30,371)
Cash flows from investing activities	
Sale of marketable securities	65,546
Purchases of property, plant, and equipment	(11,506)
Net cash provided by investing activities	54,040
Cash flows from financing activities	
Payments on capital lease obligations	(36)
Repayment of notes payable	(3,500)
Payment for capital distribution	(121,253)
Payment of retention fund for partnership interests	(1,050)
Net cash used in financing activities	(125,839)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(414)
Net decrease in cash, cash equivalents and restricted cash	(102,584)
Cash, cash equivalents and restricted cash, beginning of year (1)	215,267
Cash, cash equivalents and restricted cash, end of year (1)	\$ 112,683
Supplemental cash flow information	
Cash paid for taxes	\$ 103
Supplemental disclosure non-cash financing activities	
Equipment acquired through capital lease	\$ 63
Purchases of equipment in accounts payable	\$ 869

(1) See Note 2 for the schedule of cash, cash equivalents and restricted cash

See accompanying notes

NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

PaxVax Global, L.P. and its subsidiaries (PaxVax Global, L.P., PaxVax, or the Company) primarily focus on the development and commercialization of specialty vaccines for the overlooked traveler segment. The Company is headquartered in Redwood City, California, USA, and maintains research and development and Current Good Manufacturing Practice (CGMP) facilities in San Diego, California, USA, and in Thörishaus, Switzerland. The Company sells and distributes vaccines in the United States, United Kingdom, Italy, Spain and Switzerland. The Company is also in the business of marketing and selling priority review vouchers (PRV) we may obtain by developing new drug and biological products for the prevention and treatment of certain tropical diseases which qualify for U.S. Food and Drug Administration (FDA) PRV status. In 2016, the Company obtained its first priority review voucher from the U.S. FDA upon approval of its application for a biological license for Vaxchora, a Cholera vaccine. The voucher was subsequently sold for \$290.0 million to a third party. The Company uses the list of U.S. FDA qualified PRV eligible tropical diseases as a basis for defining its portfolio of research and development projects.

The Company's commercial portfolio includes Vivotif, a Typhoid vaccine, and Vaxchora, a vaccine for Cholera. The Company began recognizing net product revenues from sales of Vaxchora and related cost of sales in 2016. The Company also distributes Dukoral and Ixiaro for Valneva Austria GMBH in Italy, Spain, and Portugal. The clinical-stage product portfolio includes a licensed vaccine for chikungunya that is currently in phase 2 trials, adenovirus strains 4 and 7, and adenovirus-based vaccines for pandemic H5N1 influenza, and HIV all of which have included phase 1 clinical trials. The Company's proprietary adenoviral-based technology platform is intended to provide a platform technology for the rapid development of oral vaccines that can target both viral and bacterial antigens, and to be suitable for use in both developed and developing countries. In addition, the Company has preclinical vaccine candidates for the mosquito-borne Zika virus.

PaxVax, Inc. was incorporated in Delaware in 2006 and commenced operations in 2007. On December 3, 2015, PaxVax, Inc. effected a recapitalization in which a newly formed company, PaxVax Global, L.P., became its parent holding company of the worldwide consolidated subsidiaries. Simultaneous with this transaction, existing investors of PaxVax, Inc. became the sole owners of PaxVax Global, L.P. through a newly formed company, 2015 Shareholder Holding Company Limited (Holding Company). Holding Company and PaxVax Global G.P. (the general partner of PaxVax Global, L.P. and controlled by Holding Company) were the original sole owners of PaxVax Global, L.P. On December 4, 2015, Cerberus PaxVax, L.P. (Cerberus PaxVax), an affiliate of Cerberus Capital Management, L.P. (Cerberus) acquired a 70% interest in PaxVax Global, L.P. for a net cash amount of \$102.0 million (the Cerberus Transaction). Concurrent with the acquisition, Holding Company also transferred its interests in and control of PaxVax Global G.P. to Cerberus PaxVax Global GP Holdings, Ltd., an affiliate of Cerberus. The Holding Company holds the remaining 30% interest in the Company, (together referred to as the Partnership). The Company used some of the funding to pay off a majority of its debt, and amended the terms of its remaining debt. As part of the Cerberus transaction, \$1.1 million was held in restricted cash as retention for insurance claims for a specific period of time. This amount was subsequently paid to Holding Company in January 2017.

Liquidity and going concern -The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception except for the fiscal 2016 year, and expects to incur losses for the foreseeable future primarily due to research and development costs for its potential product candidates. The Company believes that its cash and cash equivalents of \$30.1 million at December 31, 2017, expected revenues and funds from future financings will be sufficient to allow the Company to fund its current operations through at least calendar year 2018. The Company's ultimate success will largely depend on its continued development of its vaccine products, its ability to successfully commercialize its products and its ability to raise significant additional funding. Various internal and external factors will affect whether and when the Company's product candidates become approved and how significant their market share will be, some of which are outside of the Company's control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the vaccine approval process will materially affect the Company's financial condition and future operations. The Company will seek additional sources of funding in the form of debt financing or equity issuances, however, there can be no assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable to it, the Company may have to significantly reduce its operations or delay, scale back or discontinue the development of one or

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

more of its products. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

Basis of presentation and principles of consolidation - The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP), and include the accounts of PaxVax Global, L.P. and its wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. The Company's consolidated financial statements do not reflect Cerberus PaxVax's new basis of accounting for the Company's assets and liabilities because the Company did not elect to apply pushdown accounting to its consolidated financial statements.

Use of estimates - The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. PaxVax's management regularly assesses these estimates, which primarily affect net product revenue, the valuation of accounts receivable, the valuation of acquired intangible assets, the impairment of long-lived assets, the valuation of accrued liabilities, the valuation of certain liabilities carried at fair value including pension liability and certain debt, the valuation of investments, stock-based compensation, and the valuation of allowances associated with deferred tax assets. Actual results could differ from those estimates.

Foreign currency translation and transactions - The consolidated financial statements are denominated in U.S. dollars. The financial statements of the Company's subsidiaries are measured using the local currencies as the functional currencies. The Company's results of operations and cash flows are subject to fluctuations due to changes in foreign currency exchange rates. Assets and liabilities of these subsidiaries are translated at the rates of exchange in effect at the respective balance sheet dates. Income and expense items are translated at the average monthly rate of exchange during the reporting period. Net unrealized gains or losses resulting from the translation of foreign financial statements are reported as a component of accumulated other comprehensive loss on the consolidated balance sheets.

Monetary assets and liabilities denominated in currencies other than the respective functional currencies are initially recorded using the foreign currency exchange rates at the time such transactions arise. The value of these receivables and payables is subject to changes in currency exchange rates from the point at which the transactions are originated until the settlement in cash. Subsequent re-measurement at each balance sheet date is recognized as transaction gains and losses in income as unrealized or realized upon settlement of the transaction. Foreign currency transaction gains or losses were not significant for the periods presented.

Fair value measurements - Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. The Company elected to apply the fair value option to account for certain financial instruments discussed in Note 6 due to the terms that allow for several unique settlement alternatives.

Cash and cash equivalents - The Company considers all highly liquid investments with an original maturity of three months or less from date of purchase to be cash equivalents. Cash and cash equivalents are comprised of cash held primarily in money market accounts.

Restricted cash - As of December 31, 2017, restricted cash of \$82.6 million represents the amount that would have been distributed to Holding Company in January 2017 if it had elected to receive a distribution from PaxVax Global at the same time as Cerberus received a distribution. Holding Company retains a (i) preference right with respect to this money in the event of future distributions authorized by PaxVax Global and (ii) right to consent to the use of this money except in specified limited circumstances (e.g., specified permitted investments by PaxVax Global or as compelled by law in connection with the insolvency, bankruptcy or dissolution of PaxVax Global).

Marketable securities - The Company determines the appropriate classification of its marketable securities, which consist primarily of debt securities, at the time of purchase, and reevaluates such designation at each balance sheet date. All marketable securities are considered available-for-sale and carried at estimated fair value and reported in short-term investments or long-term investments based on management's intent for the use of the funds, and ability to hold the investments to long-term. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive loss as a separate component of partnership interests. The Company uses the specific-identification method to compute gains and losses on the investments.

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that the Company will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, the Company reduces the carrying value of the security and records a loss for the amount of such decline.

Accounts receivable, unbilled receivables and allowance for doubtful accounts - The Company's receivables consist primarily of amounts due from product sales and balances due from performing research and development under grants and contracts with the U.S. government and other private parties. Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, prompt pay discounts accrual and an allowance for doubtful accounts. Estimates for wholesaler chargebacks for government and other programs and prompt pay discounts are based on contractual terms and historical trends. Estimates of the allowance for doubtful accounts are determined based on individual customer circumstances, an analysis of days' sales outstanding by geographic region, and a review of the local economic environment. As of December 31, 2017, trade receivables from product sales was \$1.9 million. Research contracts receivables were \$1.2 million as of December 31, 2017 of which \$0.7 million was recorded as accounts receivable and \$0.5 million as earned but unbilled revenue included in prepaid expenses and current other assets. As of December 31, 2017, one customer accounted for 23% of total accounts receivable from product sales and one customer accounted for 96% of total accounts receivable from research contracts.

The allowance for doubtful accounts is based on the Company's assessment of the collectability of its customer accounts. As of December 31, 2017, the allowance for doubtful accounts was \$83,000.

Concentration of risk - Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, investments, restricted cash and derivative financial instruments. To date, the Company has not experienced any losses on its cash and cash equivalents as a result of credit risk. The Company's investment policy, approved by the Board of Directors, includes requirements that short term credit ratings must be rated A-1, P-2, F2, or better by two of the three Nationally Recognized Statistical Rating Organizations, and long term securities must be rated at least A-2 or better by Moody's, A or better by S&P, and A or better by Fitch ratings, thereby reducing credit risk concentrations.

The Company manufactures Vivotif at its facility in Switzerland and Vaxchora at its facility in California. The facility to manufacture these products must meet Current Goods Manufacturing Process (CGMP) standards and other regulatory requirements. If the Company's manufacturing operations at these sites were interrupted for any reason, the Company may be unable to ship its commercial products or to supply its product candidates for clinical trials.

Property, plant, and equipment - Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Land is carried at historical cost. Depreciation for property, plant and equipment is computed using the straight-line method over the estimated useful lives of the respective assets, generally two years for computer equipment and software, three years for furniture, fixtures and other office equipment including telephones, and three to thirty years for laboratory and production machinery. Leasehold improvements are amortized over their estimated useful lives or the remaining lease term, whichever is shorter. Maintenance and repair costs are charged as expense to the Company's consolidated statements of operations and comprehensive income (loss) when incurred.

Identifiable intangible assets - Acquired intangible assets are amortized over their useful lives and are comprised of developed technology of \$2.5 million and trade name of \$1.1 million. The remaining useful life of the intangible assets as of December 31, 2017 is 17 years.

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Intangible assets subject to amortization as of December 31, 2017 were as follows (in thousands):

	December 31, 2017		
	Gross Carrying Amount	Accumulated Amortization	Net Book Value
Developed technology	\$ 2,500	\$ (427)	\$ 2,073
Trade name	1,100	(188)	912
Total	<u>\$ 3,600</u>	<u>\$ (615)</u>	<u>\$ 2,985</u>

The Company recorded amortization expense of \$0.2 million included in general and administrative expenses during the year ended December 31, 2017. As of December 31, 2017, the Company expects amortization expense in future periods to be as follows (in thousands):

Year Ending December 31,	
2018	\$ 180
2019	180
2020	180
2021	180
2022	180
Thereafter	2,085
Total expected amortization expense	<u>\$ 2,985</u>

Impairment of long-lived assets - The Company accounts for the impairment and disposal of long-lived assets in accordance with Accounting Standards Codification (ASC) 360, Property, Plant, and Equipment. Long-lived assets to be held and used are reviewed for events or changes in circumstances that indicate that their carrying value may not be recoverable. The Company periodically reviews the carrying value of long-lived assets to determine whether or not impairment to such value has occurred. The Company believes the future cash flows to be received from the use of the long-lived assets exceed the assets' carrying value and, accordingly, has not recognized any impairment losses as of December 31, 2017.

Revenue recognition - The Company generates revenue primarily from product sales, sales of PRVs, and government grants and other research contracts.

Revenues are recognized when all four of the following criteria are met: (i) persuasive evidence that an arrangement exists, (ii) delivery of the products or services has occurred, (iii) fees are fixed or determinable, and (iv) collectability is reasonably assured.

The Company recognizes revenue from product sales when the goods are delivered and title and risk of loss pass to the customer. Upon recognition of revenue from product sales, provisions are made for estimated product returns, prompt pay discounts, wholesaler fees, chargebacks, and rebates as appropriate. The net revenue adjustments were approximately \$7.0 million or 17%, of gross sales for the year ended December 31, 2017. Items deducted from gross product sales are as follows:

Product Returns - The Company does not provide its customers with a general right of product return, but typically permit returns if the product is damaged or defective when received by the customer, or in the case of product sold in the United States and certain countries outside the United States, if the product has expired. The Company generally will only accept returns for product that had expired up to six months after that date. In Spain, the Company accepts the return up to one year after the expiration date as required by local laws. The Vivotif product replacement program allows healthcare providers who have purchased Vivotif directly from PaxVax or from a third party, to replace up to five units of Vivotif per calendar year for issues related to improper patient administration or storage by patients. A credit will be issued or a replaced product will be shipped to providers with eligible request. The Company's estimates for expected product returns are primarily based on an ongoing analysis of its historical returns patterns, monitoring inventories held by the

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Company's distributors' product expiration dates. The Company estimates returns for Vaxchora primarily based on product returns experience of similar products, other available information pertinent to the intended use and marketing of Vaxchora. The estimated process also utilizes visibility into the distribution channel in order to determine what quantities, if any, were eligible to be returned because product is directly shipped by the Company to a limited number of customers. The provision for returns is recorded as a reduction to product revenue in the period in which the revenue is recognized, with a corresponding liability in the consolidated balance sheet.

Chargebacks - The Company provides discounts to certain healthcare providers or other customers based on contractual arrangements or statutory requirements. The Company estimates chargebacks based on estimated wholesaler inventory levels, current contract prices and historic utilization rates. Chargebacks are recorded as a reduction of product revenue and accounts receivable when revenue is recognized.

Wholesaler Fees - The Company pays fees to certain U.S. wholesalers and distributors based on contractually determined rates as a percentage of its gross sales. The Company records wholesaler fees as a reduction to product revenue when revenue is recognized, with a corresponding liability in the consolidated balance sheet.

GPO Fees - The Company is a member of a certain Group Purchasing Organization (GPO) to offer the products to its members. The GPO membership fees are deducted from gross revenue. The Company accrues for such GPO fees at historical rates based on gross sales as a reduction to revenue and corresponding liability when product revenue is recognized. The fees are subsequently paid to members based on sales volumes for each of the GPO members.

Prompt Pay Discounts - As an incentive for prompt payment, the Company offers a cash discount to certain customers, generally 2% of the customers' invoice balance. The Company estimates cash discounts based on contractual terms, utilization rates and the expectations regarding the customer complying with the contractual terms to earn the discount. The Company records the discount as an allowance against accounts receivable and a reduction of product revenue when revenue is recognized.

Grant and contract revenue consists primarily of cost-plus arrangements or research grants with the U.S. government or private parties. Government funded research contract revenue from cost-plus contracts are recognized as costs are incurred on the basis of direct costs plus allowable indirect costs. Grant revenue are earned when expenditures relating to the projects under these awards are incurred.

Grant and contract revenue is derived primarily from the U.S. government. Such contracts have certain risks which include dependence on future appropriations and administrative allotment of funds and changes in government policies. Costs incurred under U.S. government grants and contracts are subject to audit.

During the year ended December 31, 2017, \$27.4 million or 69% of total net revenues accounted for total domestic revenue from product revenue, and grant and contract revenue and \$12.2 million or 31% of total net revenues accounted for total international revenue from product revenue.

During the year ended December 31, 2017, the Company recognized revenue from three significant customers which amounted to 22%, 18%, and 16% of total revenues.

Inventories — Inventories are recorded at the lower of cost or net realizable value. Cost is determined on the first-in, first-out method. The composition of inventory is periodically reviewed in order to identify obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, a write-down to net realizable value of the inventory will be recorded in the period that the impairment is first recognized.

When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management's judgment, the Company capitalizes pre-launch inventory costs prior to regulatory approval. A number of factors are taken into consideration, including the current status in the regulatory approval process, potential impediments to the approval process such as safety or efficacy,

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

anticipated research and development initiatives that could impact the indication in which the compound will be used, viability of commercialization and marketplace trends. The Company has no capitalized pre-launch inventory as of December 31, 2017.

Inventories as of December 31, 2017 are comprised of the following (in thousands):

	December 31, 2017
Work in process	\$ 12,983
Raw materials	1,258
Finished Goods	3,376
	\$ 17,617

Shipping and handling costs - Shipping and handling costs incurred for inventory purchases are capitalized as part of inventory. Shipping and handling costs incurred for product shipments are recorded in cost of sales in the consolidated statements of operations and comprehensive income (loss).

Research and development costs - Research and development costs are expensed as incurred and consist of direct and indirect internal costs related to specific projects, as well as fees paid to other entities that conduct certain research activities on the Company's behalf. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or services are rendered.

Advertising costs — Advertising costs are expensed in the period in which they are incurred. For the year ended December 31, 2017, advertising expenses were approximately \$2.5 million.

Clinical trial accruals - Clinical trial costs are a component of research and development expenses. The Company records accruals for estimated clinical trial costs, comprising payments for work performed by contract research organizations and participating clinical trial sites. The Company accrues costs for clinical trials performed by contract research organizations based on estimates of work performed under the contracts. Costs of setting up clinical trial sites for participation in trials are expensed over the set-up period.

Share-based payments - Holding Company established the PaxVax Founders' Incentive Unit Plan (PFIUP) and has granted PFIUP units to certain employees, executives and Board members of the Company. The PFIUP units contain a performance condition and vest over various terms up to 48 months. If a Liquidity Event occurs during the term of the PFIUP, all units become fully vested. The Company records stock-based compensation expense for the PFIUP shares considered modification awards because they are associated with the termination of the legacy PaxVax, Inc. stock option plan at the time of the Cerberus acquisition. For the year ended December 31, 2017, the Company recognized compensation expense associated with this modification of \$0.4 million. As of December 31, 2017, the remaining unamortized compensation expense of \$0.3 million is expected to be amortized over a remaining weighted-average period of 0.8 year.

Total stock-based compensation expense included in the consolidated statements of operations and comprehensive income (loss) was as follows (in thousands):

	Year Ended December 31, 2017
Cost of sales	\$ 44
Research and development	164
General and administration	98
Sales and marketing	76
Total	\$ 382

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Income taxes - The Company accounts for income taxes under ASC 740, Income Taxes. Under ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for deferred tax assets when it is more likely than not that those assets will not be recovered.

The accounting guidance on accounting for uncertainty in income taxes prescribes a recognition threshold and measurement attribute criterion for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company's policy is to recognize interest and penalties in income tax expense when incurred.

Recent Accounting Pronouncements Not Yet Adopted

In August 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-15, Classification of Certain Cash Receipts and Cash Payments. ASU No. 2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments in the statement of cash flows by adding or clarifying guidance on eight specific cash flow issues. ASU No. 2016-15 is effective for fiscal years beginning after December 15, 2017, and for interim periods within that fiscal year. The new accounting pronouncement is not expected to have a significant impact on the Company's consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), and additional ASUs subsequently during 2018, which requires lessees to recognize a liability associated with obligations to make payments under the terms of the arrangement in addition to a right-of-use asset representing the lessee's right to use, or control the use of the given asset assumed under the lease. The standard will be effective for the Company in 2020. Early adoption is permitted. The Company is currently evaluating this new standard and the impact it will have on its consolidated financial statements.

In May 2014, the FASB issued ASU 2014-09, Revenues from Contracts with Customers (Topic 606). Since May 2014, additional ASUs have been issued that addresses certain implementation issues that have surfaced since the issuance of ASU No. 2014-09. This guidance applies to any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards. The core principle of this guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance supersedes existing revenue recognition guidance, including most industry-specific guidance, as well as certain related guidance on accounting for contract costs. In July 2015, FASB deferred the adoption dates of this standard whereby the standard becomes effective for the Company in 2019. Early adoption is permitted for nonpublic entities. An entity should apply the guidance using one of two methods: retrospectively to each prior reporting period presented with practical expedients or retrospectively with the cumulative effect of initial adoption of the guidance recognized at the date of initial application. The Company is currently evaluating the impact of adopting this standard on its consolidated financial statements and disclosures.

Adopted Accounting Pronouncements

Beginning in the year ended December 31, 2016, the Company early adopted ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. ASU No. 2016-18 requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and restricted cash. As a result, restricted cash for the year ended December 31, 2017 of \$82.6 million, is included with cash, cash equivalents and restricted cash when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new guidance was applied retrospectively to all periods presented.

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes, which requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The new accounting standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early application is permitted as of the beginning of an interim or annual reporting period. The Company adopted ASU 2015-17 prospectively as of December 31, 2016. The adoption of the new standard did not have a significant effect on the Company's consolidated financial statements.

In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU No. 2015-11 requires an entity to measure inventory at the lower of cost and net realizable value when the FIFO or average cost method is used. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, and should be applied prospectively. Earlier adoption is permitted. The adoption of the new standard did not have a significant effect on the Company's consolidated financial statements.

In April 2015, the FASB issued ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. ASU 2015-03 simplifies the presentation of debt issuance costs by requiring such costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. Recognizing debt issuance costs as a deferred charge is no longer permitted for term debt. This update is effective for financial statements issued for fiscal years beginning after December 15, 2015. Early adoption is permitted for financial statements that have not been previously issued. The new guidance should be applied on a retrospective basis with the balance sheet of each individual period presented adjusted to reflect the period-specific effects of applying the new guidance. The adoption of this standard by the Company in January 2016 did not have a material effect on the Company's consolidated financial position and results of operations or disclosures.

In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to continue as a Going Concern. ASU 2014-15 provides guidance on management's responsibility in evaluating whether there is substantial doubt about a company's ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company's adoption of this standard for the year ended December 31, 2016 did not have a significant impact on the Company's consolidated financial position and results of operations or disclosures. The Company has accordingly complied with the footnote disclosures requirement.

NOTE 2 — BALANCE SHEET COMPONENTS

Property, Plant and Equipment

Property, plant and equipment consist of the following for the year ending December 31, 2017 (in thousands):

	December 31,
	2017
Laboratory and production machinery	\$ 21,582
Buildings	14,337
Land	921
Leasehold improvements	4,175
Computer equipment and software	4,103
Furniture and fixtures	574
Property, plant and equipment, gross	45,692
Less accumulated depreciation and amortization	(17,290)
Property, plant and equipment, net	28,402
Construction in process	10,204
	\$ 38,606

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Depreciation and amortization expense was \$4.1 million for the year ended December 31, 2017. Amortization of capitalized software is included in depreciation and amortization expense, which is expensed over a two to five year period. Amortization of capitalized software for the year ended December 31, 2017 was \$0.6 million.

Equipment purchased under capital leases was \$0.1 million during the year ended December 31, 2017.

Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the statement balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows as of December 31, 2017 (in thousands):

	<u>December 31,</u> <u>2017</u>
Cash and cash equivalents	\$ 30,059
Restricted cash	82,624
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows	<u>\$ 112,683</u>

Accrued Liabilities

Accrued liabilities as of December 31, 2017 consisted of the following (in thousands):

	<u>December 31,</u> <u>2017</u>
Accrued compensation and benefits	\$ 6,870
Sales returns and sales-related accruals	1,970
Clinical trial related accruals	424
Professional services	910
Other accruals	1,615
	<u>\$ 11,789</u>

NOTE 3 - FAIR VALUE MEASUREMENT

The accounting guidance for fair value states that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value, as follows:

Level 1— Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2— Directly or indirectly observable inputs other than in Level 1 that include quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active.

Level 3— Unobservable inputs that are supported by little or no market activity that reflect the reporting entity's own assumptions about the assumptions that market participants would use in pricing the asset or liability.

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

The Company estimate the fair values of its corporate debt securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker or dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; prepayment or default projections based on historical data; and other observable inputs.

The following table summarizes the assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):

	December 31, 2017			
	Level 1	Level 2	Level 3	Total
Assets:				
Money market funds	\$ 73,578	\$ —	\$ —	\$ 73,578
Corporate debt securities(1)	—	15,011	—	15,011
Cash	24,094	—	—	24,094
Total	<u>\$ 97,672</u>	<u>\$ 15,011</u>	<u>\$ —</u>	<u>\$ 112,683</u>
Liabilities:				
Convertible unsecured loans	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 12,091</u>	<u>\$ 12,091</u>

(1) Corporate debt securities is classified as restricted cash on the consolidated balance sheets for the year ending December 31, 2017.

There were no transfers between Level1, Level 2 and Level 3 during the periods presented.

Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table is a summary of available-for-sale securities (in thousands):

	December 31, 2017		
	Amortized Cost	Gross Unrealized Losses	Estimated Fair Value
Money market funds	\$ 73,578	\$ —	\$ 73,578
Corporate debt securities (1), (2)	15,023	(12)	15,011
Total	<u>\$ 88,601</u>	<u>\$ (12)</u>	<u>\$ 88,589</u>

(1) The available-for-sales securities have been in a continuous unrealized loss position for greater than 12 months.

(2) Corporate debt securities is classified as restricted cash on the consolidated balance sheets for the year ended December 31, 2017.

(3) The available-for-sales securities have been in a continuous unrealized loss position for less than 12 months.

The following table presents the contractual maturities of available-for-sale securities as of December 31, 2017 (in thousands):

	December 31, 2017	
	Amortized Cost	Estimated Fair Value
Due in one year or less	<u>\$ 15,023</u>	<u>\$ 15,011</u>

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Based on the Company's review of its available-for-sale securities, the Company believes there were no other-than-temporary impairments on these securities as of December 31, 2017. The Company does not intend to sell these securities nor believes that it will be required to sell these securities before the recovery of their amortized cost. Gross realized gains and gross realized losses were immaterial for the year ended December 31, 2017.

The following table reconciles the assets measured at fair value on a recurring basis in the tables above to the consolidated balance sheets (in thousands):

	<u>December 31,</u> <u>2017</u>
Cash and cash equivalents	\$ 30,059
Restricted cash	82,624
Short-term investments	—
Long-term investments	—
Total	<u>\$ 112,683</u>

As of December 31, 2017, financial instruments measured using Level 3 inputs on a recurring basis consisted of convertible unsecured loans where the Company has elected the fair value option to account for these financial instruments.

The Company estimates the fair value of the convertible unsecured loans using a discounted cash flow model based on the probability of a Winding-Up Event, as defined, amount and timing of expected payouts and an assumed discount rate. The Company will continue to adjust the liability for changes in fair value until the earlier of the repayment of the principal and interest of the loans, or a Winding-Up Event occurs.

Activity for the fair value of the convertible unsecured loans using significant unobservable inputs (level 3) is presented in the table below (in thousands):

	<u>Convertible</u> <u>Unsecured Loan</u>
Balance at December 31, 2016	\$ 12,701
Adjustment to fair value included in earnings	(610)
Balance at December 31, 2017	<u>\$ 12,091</u>

NOTE 4 —COMPREHENSIVE (LOSS) INCOME

Comprehensive (loss) income is comprised of net (loss) income and other accumulated comprehensive (loss) income. As of December 31, 2017, other accumulated comprehensive income (loss) is comprised of unrealized losses on the Company's pension plan for its employees in Switzerland, a net unrealized gain (loss) on investments, and the impact of foreign currency translation.

The following table summarizes the changes in accumulated other comprehensive loss by component (in thousands):

	<u>Pension</u> <u>Liability</u>	<u>Foreign</u> <u>Currency</u> <u>Translation</u>	<u>Investments</u> <u>in Marketable</u> <u>Securities</u>	<u>Total</u>
As of December 31, 2016	(3,075)	(522)	(159)	(3,756)
Unrealized gains (losses) arising during the period	(1,571)	348	147	(1,076)
As of December 31, 2017	<u>\$ (4,646)</u>	<u>\$ (174)</u>	<u>\$ (12)</u>	<u>\$ (4,832)</u>

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The effect of income taxes for the year ended December 31, 2017 on these balances is immaterial.

NOTE 5 - COMMITMENTS AND CONTINGENCIES

Operating Leases — The Company's office and manufacturing facilities located in San Diego and Redwood City, California, are subject to noncancelable operating lease agreements. The Company provided aggregate cash deposits of \$0.2 million as security for the operating leases, as of December 31, 2017. The cash deposits related to property leases were recorded in prepaid expenses and other current assets and other long-term assets within the Company's consolidated balance sheet.

Included within the lease agreements are tenant improvement allowances totaling approximately \$0.4 million. The Company is amortizing the portion of the deferred rent liability related to the tenant improvement allowances as a reduction to rent expense over the remaining term of the lease.

The Company's leases contain rent escalation clauses. Rent expense is recorded on a straight-line basis over the term of the leases. The difference between the base rent payment and the straight-line rent amount is recorded as a deferred rent liability. As of December 31, 2017, the Company has deferred rent liabilities of approximately \$0.1 million included in other current liabilities and \$0.1 million included in other long term liabilities in the consolidated balance sheet. Rent expense, including common area charges, was \$1.6 million for the year ended December 31, 2017.

Future minimum commitments under the lease agreements as of December 31, 2017 are as follows (in thousands):

Year Ending December 31,		
2018	\$	1,361
2019		976
2020		607
2021		553
2022		48
Thereafter		3
Total minimum lease payments	\$	<u>3,548</u>

Licensing Agreements - The Company has entered into licensing agreements with certain parties, whereby the Company has been granted exclusive and nonexclusive licenses to certain patented technology and know-how of certain additional proprietary technology. In addition to licensing fees, the agreements obligate the Company to pay royalties to the Licensors on certain milestones and revenue generated from the Company's use of the licensed patents and technology, including product sales revenue and proceeds from sublicensing agreements.

The agreements typically terminate on the last to expire patent right associated with the related agreement. The agreements obligate the Company to make annual licensing payments until expiration. For the year ended December 31, 2017, amounts due and recognized for licensing, royalty, and patent reimbursement fees were immaterial.

NOTE 6 - DEBT FINANCING

A summary of debt outstanding at December 31, 2017 is as follows (in thousands):

	December 31, 2017		
	Current	Long Term	Total
Related party convertible notes payable	\$ —	\$ 7,090	\$ 7,090
Convertible unsecured loans	—	12,091	12,091
	<u>\$ —</u>	<u>\$ 19,181</u>	<u>\$ 19,181</u>

Related Party Convertible Notes Payable

In September 2015, the Company executed convertible promissory notes and received \$7.0 million in net cash proceeds from an investment fund that held two of five of the Company's Board of Director seats and a controlling voting interest in the Company at that time. The terms of the notes bear interest at 0.56% per annum and that all unpaid principal and accrued interest are due upon the earlier of (i) the demand of the holders of a majority of the principal outstanding on or after December 31, 2015; (ii) the next business day following the date on which payment in full is made by the Company to its third-party lender; (iii) demand of the majority holders following an event of default; or (iv) the election of the majority holders in the event of an acquisition.

In December 2015, the terms of the \$7.0 million convertible promissory note were amended. All outstanding principal and all accrued but unpaid interest under the note is due and payable upon demand at any time on or after the occurrence of: a winding up and/or dissolution of the partnership; a sale or exclusive license of all or substantially all of the assets of the partnership or its subsidiaries to an unrelated third party; a merger, acquisition, or sale of partnership interests; in which the partners immediately prior to such event have received consideration for no less than half of the value of their partnership interests, or upon default. In the event Cerberus or its affiliate proposes to make an additional investment into the partnership, the note may also be converted into common limited partnership interests of PaxVax Global, L.P., in accordance with, and subject to, certain terms and provisions. The amendment to the convertible promissory notes was considered to be a modification and accounted for prospectively as it did not result in a significant change in their fair value.

Convertible Unsecured Loans

In June 2008, the Company received strategic award funding in the amount of \$12.8 million (First Award). In June 2010, the Company received a second strategic award funding in the amount of \$3.0 million (Second Award). These awards are from a charitable foundation trust, The Wellcome Trust Limited (Wellcome Trust), in the form of convertible unsecured loans (Loans) related to certain research and development programs. As of December 31, 2017, the Company had outstanding borrowings of \$15.8 million in total from both awards.

The Loans initially accrued interest at 2.00% above the NatWest Bank plc base rate. At Wellcome Trust's discretion, it could require the Company to convert some or all of the respective Loans into the next round of financing offered by the Company at the earlier of certain events or upon an event of default. The strategic award with Wellcome Trust also did not allow them to require the Company to repay the award if such repayment would have caused doubts as to the Company's ability to continue as a going concern.

On December 4, 2015, the Master Amendment Deed (the Deed) was signed by and among PaxVax Inc., The Wellcome Trust Limited, and PaxVax Global, L.P., which amended the original agreement and stated that, effective upon the Deed, Wellcome Trust shall not demand conversion of each Loan and demand repayment of any Loan (or part thereof) or accrued interest. The only automatic conversion will occur upon a Winding-Up Event, as defined in the deed, such as a dissolution, sale, merger, acquisition, recapitalization or reorganization of the partnership or a material breach of the Company's obligations under the Funding Agreement. In the Deed, all parties agreed that, upon the occurrence of a Winding-Up Event after the effective date of the Deed, only the principal amounts of both First and Second Awards will be converted to common limited partnership interests of PaxVax Global, L.P., and all accrued interest under each award shall be extinguished.

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The Company elected to apply the fair value option to account for the Loans. As of December 31, 2017, the Company is in compliance with its covenant obligations under the Funding Agreement.

As of December 4, 2015, the date of the Deed, the accrued interest that has not been recorded was \$2.9 million. Thus the Deed released the Company's liability to any accrued interest. As the Company has elected the fair value option to account for the Loans, the change in fair value was recorded as part of the fair value adjustment in the consolidated statements of operations for the year ended December 31, 2017

The carrying value of the Loans at December 31, 2017 is as follows (in thousands):

	First Award	Second Award	Total
Principal amount of award	\$ 12,765	\$ 2,999	\$ 15,764
Cumulative change in fair value	(2,974)	(699)	(3,673)
Total carrying value	<u>\$ 9,791</u>	<u>\$ 2,300</u>	<u>\$ 12,091</u>

Royalty Obligation Payable

In July 2014, the Company executed a secured loan and security agreement with a previous third-party lender for an available loan amount of up to \$50.0 million in three tranches subject to certain requirements at the date of funding. In December 2015, the Company terminated all commitments under the loan agreement, except for payment of future royalties (royalty obligation payable), by repaying the obligations and liabilities under the agreement which comprised full repayment of the outstanding principal and accrued interest of the then-outstanding debt and certain prepayment penalties and fees.

The Royalty Obligation Payable contains repayment terms of future royalties estimated by the Company at \$2.9 million as of December 31, 2015. These future royalties are computed at 3% of the Company's revenues earned and payable to the lender in three yearly payments beginning on September 15, 2017. The Company records the net present value of the estimated expected future royalty payments as a liability, and accretes interest expense based on the future payment dates. A new effective interest rate is computed when the estimated future payments change, and the carrying amount of the royalty obligation payable liability is adjusted as if the new effective interest rate had been used since inception. Interest expense is recognized at the new effective rate beginning in the period in which the change in estimate occurs.

As of December 31, 2016, the royalty repayment amount of \$4.1 million represents the estimated fair value of future royalties, and is presented as current and noncurrent royalty obligation payable in the Consolidated Balance Sheets. In June 2017, the royalty obligation payable was settled for \$3.5 million. The extinguishment of royalty obligation resulted in a gain of \$0.6 million, which the Company recognized in the consolidated statements of operations and comprehensive (loss) income in the year ended December 31, 2017.

NOTE 7 - FOUNDERS' UNITS

PaxVax Founders' Incentive Unit Plan

On December 4, 2015, Holding Company established the PaxVax Founders' Incentive Unit Plan (PFIUP). Under the PFIUP, 50,000,000 units were reserved for grant of which 30,180,412 units were subsequently awarded to certain holders of outstanding awards in the PaxVax, Inc.'s 2007 Equity Incentive Plan (the Plan) which was terminated in 2015. These shares are known as modification units because they qualify for modification treatment of share based payments under US GAAP.

As of December 31, 2017, 48,352,549 units had been awarded to participants of which 19,853,684 units were fully vested as of January 1, 2016. As of December 31, 2017, 36,663,495 PFIUP units were fully vested, respectively. As of December 31, 2017, there were 11,689,054 PFIUP units outstanding. The remaining units vest over various terms up to 48 months and are divided between shares subject to modification accounting treatment and Top-Up units not subject to modification treatment. All PFIUP units automatically vest upon a Liquidity Event which is defined as a winding up, dissolution, sale of all assets, merger or similar corporate event of PaxVax Global, L.P. or

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

IPO of PaxVax Global, L.P. or PaxVax, Inc. Participants who hold vested Incentive Units at the time of any other dividend or distribution to holders of common stock of Holding Company or at the time of a Liquidity Event will be entitled to a cash payment. The Company recognizes compensation expense for the original grant date fair value of the modified shares over the remaining vesting period. The Company did not recognize any compensation expense related to the PFIUP Top-Up units for the year ended December 31, 2017 because the occurrence of the performance condition required for payment associated with these awards was not considered to be probable and therefore there is no fair value associated with these units.

The following represents the PFIUP activity for the year ended December 31, 2017:

	Units Available for Issuance	Unvested Units Outstanding		
		Total	Modification units	Top-Up units
Balance at December 31, 2016	753,384	19,751,269	5,015,180	14,736,089
Issued	(638,000)	638,000	—	638,000
Vested	—	(7,168,148)	(2,582,714)	(4,585,434)
Forfeited	1,532,067	(1,532,067)	(592,386)	(939,681)
Balance at December 31, 2017	1,647,451	11,689,054	1,840,080	9,848,974

NOTE 8 - PARTNERSHIP INTERESTS

Partnership Interests

Under the Amended and Restated Exempted Limited Partnership Agreement of PaxVax Global, L.P. (the Partnership Agreement) dated December 4, 2015, the Company is authorized to issue up to 10,000,000 partnership interests. The number of preferred and common interests are authorized as the Board determines from time to time. The Partnership Agreement provides for three classes of partnership interests; the “Common Interests”, the “Preferred Interests” and the “Profits Interests” of which 2,550,000 are Common Interests, 5,950,000 are Preferred Interests and 1,500,000 are Profits Interests. The Profits Interests are equally divided into two series, 750,000 the “Series A Profits Interests” and 750,000 “Series B Profits Interests”. The number of preferred and common units are authorized as the Board determines from time to time. There were 1,173,500 Profits Interests Issued and Outstanding and 326,500 Profits Interests available for issuance as of December 31, 2017. The partners’ liability under the Partnership Agreement is limited to their undistributed capital contributions.

The general partner of the Company is PaxVax Global G.P. Limited (General Partner). Holding Company and Cerberus PaxVax are the Company’s limited partners. The limited partners do not have a right to vote on any matter except required by law. The Profits Interests do not have any voting rights under any circumstances.

Priority of Distributions

The General Partner may in its discretion make distributions from time to time pursuant to the distribution priorities as set forth in the Partnership Agreement. All distributions, other than tax distributions (as provided per the Partnership Agreement) shall be made to partnership interests holders in respect of their outstanding partnership interests only in the following order and priority:

Ordinary course distributions - First, to the Cerberus PaxVax equal to any uninsured losses associated with the Cerberus Acquisition as of the date of the distribution. Second, to the limited partners pro rata in proportion to their respective number of Preferred Interests and Common Interests. Third, to the holders of vested Series A Profits Interests pro rata in proportion to their respective number of Preferred Interests, Common Interests and vested Series A Profits Interests until an aggregate amount of no less than \$300.0 million has

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

been distributed to the Preferred Interests, Common Interests and Series A Profits Interests holders subject to the Preferred Interests and Common Interest holders first receiving distributions of no less than \$150.0 million. Fourth, to the holders of the Preferred Interests, Common Interests, vested Series A Profits Interests and vested Series B Profits Interests on a pro rata in proportion to their respective number of Preferred Interests, Common Interests, vested Series A Profits Interests and vested Series B Profits Interests.

Distributions following the receipt of PRV proceeds - Net PRV proceeds will be distributed first to Cerberus PaxVax equal to any uninsured losses associated with the Cerberus Acquisition as of the date of the distribution. Second, to Cerberus PaxVax equal to any advances it has made to partners of the Company. Third, to the holders of Preferred Interests and Common Interests on a pro rata basis of their ownership until an aggregate of no less than \$150.0 million has been distributed. Fourth to the Preferred Interests, Common Interests and vested Series A Profits Interests, pro rata in proportion to their respective number of Preferred Interests, Common Interests and vested Series A Profits Interests until no less than \$175.0 million has been distributed. Fifth, to the Preferred Interests, Common Interests and vested Series A Profits Interests holders pro rata in proportion to their respective number of Preferred Interests, Common Interests and Series A Profits Interests until no less than \$300.0 million has been distributed. The distribution is made pro rata to vested Series A Profits Interests on a fully diluted basis assuming all Common, Preferred, and vested Series A Profits Interests are outstanding with the remaining balance split equally between the Common and Preferred interest holders. Distributions thereafter are made to the Preferred Interests, Common Interests and vested Series A Profits Interests and vested Series B Profits Interests on a pro rata basis with respect to the outstanding and vested interests with the amount going to the Preferred Interests and Common interests also split equally. Certain amounts of the distributions made to the Common Interest holders are to be put into an escrow account to be applied against future investments in the Company.

Distributions upon a winding-up event - Following a winding up event, defined as a winding-up of the Company, sale or licensing or all the assets of the Company or its subsidiaries, a merger or acquisition or sale of the Company or a recapitalization or reorganization, whereby the Company receives proceeds from a financing for the purposes of distributing such proceeds to the partnership, the proceeds from the event will be distributed first to Cerberus PaxVax equal to any uninsured losses associated with the Cerberus Acquisition as of the date of the distribution. Second, to Cerberus PaxVax equal to any advances it has made to partners of the Company. Third, if the aggregate amount that has been previously distributed to the Preferred Interests holders is less than \$105.0 million plus all accrued but unpaid Preferred Interest holder dividends (the Liquidation Preference), the pari passu amount amongst the Preferred Interests holders until the Liquidation Preference has been met; however, if the Preferred Interest holders would receive more than the Liquidation Preference by participating on a pro rata basis in distributions on an equal basis as the Common Interests holder then the Preferred Interest holder will be treated as a Common Interests holder for purposes of the distribution. Forth, to the Common Interest Holders and vested Series A Profits Interest holder on a pro rata basis in proportion to their respective number of Common Interest and vested Series A Profits Interest up to \$300.0 million. Fifth, and thereafter, to the Common Interest and vested Series A and B Profits Interests on a pro rata basis in proportion to their held Common Interest and vested Series A and B Profits Interests.

Allocation of Profits and Losses of the Partnership

Profits or losses for any calendar year are allocated among the partners of the Company in such a manner that, as of the end of such calendar year, with respect to each partner of the Company, the sum of (i) the capital account of such partner, (ii) such partner's share of partnership minimum gain and (iii) such partner's partner nonrecourse debt minimum gain shall, as nearly as possible, be equal to the net amount, positive or negative, that would be distributed to such partner of the Company or for which such partner of the Company would be liable to the Company.

Dividends

The capital contribution associated with the Preferred Interests of the Company accrues a dividend of 8% cumulative and compounded quarterly in arrears, when and if declared.

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Transfers

No limited partner is allowed to transfer, offer or agree to transfer all or any parts of any interest in such partnership interests without the prior written consent of the General Partner. All General Partner approved interests transfers are subject to compliance with the terms of the Partnership Agreement.

Dissolution and Liquidation

The Company shall dissolve upon the earlier of: (i) approval of the General Partner or (ii) upon the removal, bankruptcy or withdrawal of the General Partner if a substitute cannot be implemented or (iii) upon the final distribution of all the assets and satisfaction of all liabilities of the Company. On dissolution of the Company, the General Partner shall act as liquidator or may appoint one or more representatives or interests holders as liquidator. The liquidator shall sell any portion of the Company's assets and make final distributions.

On January 24, 2017, the Partnership Agreement was amended primarily to revise clauses relating to the distribution of proceeds from the sale of PaxVax Bermuda's priority review voucher (PRV) issued in connection with the approval of Vaxchora. PaxVax Bermuda distributed to the Company \$122.2 million relating to PRV proceeds. In turn, the Company made distributions to its partners as follows: \$121.3 million was distributed to Cerberus PaxVax and \$0.9 million was distributed to Series A Profits Interests holders. Further distributions to the Company by PaxVax Bermuda, and in turn, by the Company to the Limited Partners holding Series A Profits Interests, of up to \$2.9 million were made and will be made in a series of quarterly installments from March 31, 2017 to December 31, 2019, as the Series A Profits Interests vest. For the year ended December 31, 2017, \$0.9 million had been reflected as bonus or board member fees and included in the consolidated statements of operations and comprehensive income (loss). PaxVax Bermuda retained \$82.6 million from PRV proceeds in lieu of distributing such amount to the Company for distribution to the Holding Company. These funds will be used by the Holding Company to purchase additional equity in the Company if there is a future investment opportunity in the Company. If there is no new investment opportunity, the Holding Company will receive a distribution equal to this amount in preference to any distribution to Cerberus PaxVax or holders of Profits Interests.

PaxVax Profits Interests Plan

On December 4, 2015, the Company established the PaxVax Global, L.P. Profits Interests Plan (PPIP). Under the PPIP, each participant is granted the number of profits interests set forth in the award agreement. Profits interests are subject to vesting; for which 6.25% shall vest upon each calendar quarter end date after grant date. Participants in the PPIP have the right to share in distributions of the Company as set forth in the PPIP and the Company's Partnership Agreement. Upon termination of employment of the participant with the Company or its affiliate, the Company has the right, but not the obligation, to purchase the vested portion of the participant's profits interests. The number of profit interests that are reserved for issuance under the PPIP represent 15% of the outstanding equity of PaxVax Global, L.P. of which 13% is reserved for issuance to PaxVax management and Board of Directors as of December 31, 2017. Awards of profits interest are not considered to be a substantive class of partnership ownership and are therefore accounted for as a profit sharing arrangement.

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 9 - INCOME TAXES

Income tax benefit for the year ended December 31, 2017 and consists of the following (in thousands):

	<u>December 31,</u> <u>2017</u>
Current:	
State	\$ 95
Federal	205
Foreign	291
Total current	<u>591</u>
Deferred:	
Federal	(857)
Foreign	(166)
Total deferred	<u>(1,023)</u>
Income tax benefit	<u>\$ (432)</u>

At December 31, 2017, the Company's effective tax rate was 1.1%. The effective income tax rate differed from the U.S. federal statutory rate of 34% due primarily to a valuation allowance recorded in various jurisdictions, pre-tax income (loss) subject to lower income tax rates in jurisdictions outside the U.S., the enactment of the Tax Cut and Jobs Act, and income earned at a partnership that is not subject to income tax.

The components that comprise the Company's deferred tax assets and liabilities at December 31, 2017 consist of the following (in thousands):

	<u>December 31,</u> <u>2017</u>
Deferred tax assets:	
Net operating loss carryforwards	\$ 10,101
Tax credits	5,395
Accrued salaries and wages	737
Accrued vacation	265
Deferred rent	64
Accrual and reserves	1,551
Inventory	241
Pension liability	750
Other	439
Deferred tax assets	<u>19,543</u>
Depreciation and amortization	447
Deferred tax liabilities	<u>447</u>
Less: valuation allowance	(18,011)
Net deferred tax assets	<u>\$ 1,085</u>

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company's net operating loss and research and development credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. In 2015, the Company completed a 382 and 383 study and determined that \$0.9 million of federal net operating and \$12.2 million California net operating loss deferred tax asset will be permanently disallowed. Further, \$1.8 million of federal research and development credits are permanently disallowed. The remaining balances have been recognized.

The Tax Cuts and Jobs Act was enacted on December 22, 2017. The Act reduces the US federal corporate tax rate from 34% to 21%, requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and creates new taxes on certain foreign sourced earnings. In accordance with Staff Accounting Bulletin 118, as of December 31, 2017, we have not completed our accounting for the tax effects of enactment of the Act; however, in certain cases, as described below, we have made a reasonable estimate of the effects on our existing deferred tax balances. In other cases, we have not been able to make a reasonable estimate and continue to account for those items based on our existing accounting under ASC 740, Income Taxes, and the provisions of the tax laws that were in effect immediately prior to enactment.

Deferred tax assets and liabilities: The Company remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. However, the Company is still analyzing certain aspects of the Act and refining our calculations, which could potentially affect the measurement of these balances or potentially give rise to new deferred tax amounts. The provisional amount recorded related to the remeasurement of our deferred tax balance was \$4.5 million. With a corresponding offset to the valuation allowance. Federal alternative minimum tax (AMT) credits are refundable. The Company recorded a benefit of \$0.9 million related to prior year AMT credits that are now refundable.

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax-planning strategies in making this assessment. Based on the level of historical operating results and the uncertainty of the economic conditions, the Company has recorded a valuation allowance of \$18.0 million at December 31, 2017. The change in the valuation allowance for the year ended December 31, 2017 was a decrease of \$3.3 million.

The Company files income tax returns in the United States, various states and foreign jurisdictions. Due to the Company's losses incurred, the Company is essentially subject to income tax examination by tax authorities from inception to date.

For the year ended December 31, 2017, the Company recorded \$5.5 million, gross unrecognized tax benefit. Included in the balance of unrecognized at December 31, 2017, is \$4.2 million, which if recognized, would not impact the Company tax benefit or effective tax rate as long as the deferred tax asset remains subject to a full valuation allowance. The Company's policy is to recognize interest expense and penalties related to income tax matters as income tax expense. At December 31, 2017 the Company recorded \$83,000 and \$83,000 interest and tax penalties, respectively, as of the current reporting date with respect to income tax matters. The Company is not expecting unrecognized tax benefits to increase or decrease significantly within the next 12 months.

At December 31, 2017, the Company had federal net operating losses of \$41.3 million and state tax net operating losses of \$31.4 million. The federal and state tax loss carryforwards will begin to expire in 2027 and 2028, respectively. As of December 31, 2017, the Company also has federal and state research and development tax credit carryforwards of \$3.1 million and \$4.2 million, respectively. The research tax credit for federal purposes will begin to expire in 2027, unless previously utilized. The research tax credit for state purposes will carry forward indefinitely until utilized. The Company also had federal alternative minimum tax of \$0.9 million. If certain changes in the Company's ownership should occur (or have occurred), there would potentially be an annual limitation on the amount of the tax loss carryforward that could be utilized in a tax year.

As of December 31, 2017, the Company had Foreign net operating losses of \$13.2 million. The Swiss net operating losses can be carried forward seven years and Italian net operating losses can be carried forward indefinitely.

NOTE 10 - DEFINED BENEFIT AND EMPLOYEE BENEFIT PLANS

Defined Benefit Plan

The Company sponsors a defined benefit pension plan (the Pension Plan) covering eligible Swiss employees. Other non-US, and non-Swiss employees are covered by government -sponsored programs and the cost to the Company is not significant. The Pension Plan is overseen by a board that is responsible for the overall administration of the Pension Plan.

The cost of providing the benefits is determined in accordance with the provisions of ASC 715 Compensation -Retirement Benefits. As of December 31, 2017, the Pension Plan assets comprised of an insurance contract. The contract value is presumed to be its fair value based on the practicability exception in ASC 715.

Components of net periodic pension cost incurred during the year ended December 31, 2017 are as follows (in thousands):

	<u>Year Ended</u> <u>December 31,</u> <u>2017</u>
Service cost	\$ 1,253
Interest cost	218
Expected return on plan assets	(610)
Amortization of loss	157
Amortization of prior service cost	68
Net periodic benefit cost	<u>\$ 1,086</u>

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The funded status for the year ended December 31, 2017 is as follows (in thousands):

	December 31, 2017
Fair value of plan assets, beginning of year	\$ 20,184
Employer contributions	934
Employee contributions	469
Benefits paid (refunded)	1,711
Actual administration expenses, taxes	(64)
Actual return on plan assets	225
Settlements	(4,025)
Currency impact	884
Fair value of plan assets, end of year	20,318
Projected Benefit Obligation, beginning of year	28,954
Service cost	1,165
Interest Cost	191
Employee contributions	469
Actuarial loss	372
Benefits paid (refunded)	1,711
Actual administration expenses, taxes	(64)
Plan amendment	1,733
Settlements	(4,025)
Currency impact	1,292
Projected benefit obligation, end of year	31,798
Funded status, end of year	\$ (11,480)
Accumulated benefit obligation, end of year	\$ 29,023

Effective January 1, 2018 the Pension Plan was changed from Swiss Life to Swisscanto. The plan benefits remain essentially the same except that the conversion factors used to convert the accumulated account balance into annual pension at retirement are higher resulting an impact of \$1.7 million. This amount is recognized as a prior service cost as of December 31, 2017 and will be amortized through the pension expense over the average future working lifetime of the current employee population. During the year ended December 31, 2017, total settlements of \$4.0 million were paid out.

The weighted average assumptions used to calculate the projected benefit obligations are as follows:

	December 31, 2017
Discount rate	0.70%
Expected rate of return	1.25%
Rate of future compensation increases	1.50%

Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The three levels of inputs used to measure fair value of plan assets are described in Note 3, Fair Value Measurements. The pension plan assets measured at fair value on a recurring basis consisted of insurance contract investments with level 3 inputs.

PAXVAX GLOBAL, L.P. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The overall expected long-term rate of return on assets assumption takes into account historical returns, as well as expected future returns based on the fact that investment returns are insured, and the legal minimum interest crediting rate as applicable. The amount of unrealized loss on pension liability included in accumulated other comprehensive loss expected to be recognized in net periodic benefit cost during the year ended December 31, 2017 is \$1.6 million. Funding is determined by the pension plan regulations which include a certain mandatory coverage. Total contributions expected to be made into the plan in 2018 is \$1.3 million.

The following table presents losses recognized in accumulated other comprehensive loss before income tax related to the Company's defined benefit pension plans (in thousands):

	Year Ended December 31, 2017
Net loss	\$ 4,800
Prior service cost	893
Total recognized in accumulated other comprehensive loss	<u>\$ 5,693</u>

Losses in accumulated other comprehensive loss related to the Company's defined benefit pension plans expected to be recognized as components of net periodic benefit cost over the fiscal year ending December 31, 2018 are as follows (in thousands):

Net loss	\$ 159
Prior service cost	68
Total recognized in accumulated other comprehensive loss	<u>\$ 227</u>

Future benefits expected to be paid as of December 31, 2017 are as follows (in thousands):

Year Ending December 31,	
2018	\$ 861
2019	1,626
2020	1,321
2021	939
2022	1,456
Thereafter	5,755
Total	<u>\$ 11,958</u>

Defined Contribution Plan

The Company has a 401(k) plan for all full-time employees in the United States. Employees may elect to contribute a portion of their pretax salary, not to exceed the annual limitation designated by the Internal Revenue Service, to the 401(k) plan during the year. The Company matches 4% of employee salary up to \$4,000. Matching contributions were \$0.4 million for the year ended December 31, 2017.

NOTE 11 - SUBSEQUENT EVENTS

Effective January 1, 2018 the Pension Plan was changed from Swiss Life to Swisscanto. The plan benefits remain essentially the same except that the conversion factors used to convert the accumulated account balance into annual pension at retirement are higher resulting an impact of \$1.7 million. This amount is recognized as a prior service cost as of December 31, 2017 and will be amortized through the pension expense over the average future working lifetime of the current employee population. During the year ended December 31, 2017, total settlements of \$4.0 million were paid out.

The Company evaluates events occurring subsequent to the end of the year and recognizes such events that are material in the consolidated financial statements. In the preparation of the accompanying consolidated financial statements, the Company has evaluated subsequent events through May 7, 2018, the date the financial statements were available to be issued.

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

The following unaudited pro forma condensed combined financial statements of:

- Emergent BioSolutions Inc. (“Emergent”);
- PaxVax Holding Company Ltd. (prior to the completion of the acquisition but after June 30, 2018, PaxVax Global, L.P. contributed all of its subsidiaries, operations, assets and liabilities to a newly-formed entity, PaxVax Holding Company Ltd., therefore, PaxVax Global, L.P. and PaxVax Holding Company Ltd will be collectively referred to as “PaxVax”) and the historical financial information of PaxVax Global, L.P. has been used to prepare these unaudited pro forma condensed combined financial statements; and
- Adapt Pharma Limited (“Adapt”)

have been prepared to give effect to the acquisitions of PaxVax and Adapt by Emergent.

On October 4, 2018, Emergent completed the acquisition of PaxVax pursuant to a Plan of Merger agreement dated August 8, 2018. At the closing of the transaction, Emergent paid a cash purchase price of \$270.4 million (inclusive of closing adjustments).

On October 15, 2018, Emergent completed the acquisition of Adapt, pursuant to a Share Purchase Agreement dated August 28, 2018. Emergent paid approximately \$581.5 million in cash at the closing (inclusive of closing adjustments) and issued 733,309 shares of Common Stock at \$60.44 per share for a total of \$44.3 million (inclusive of adjustments). The \$44.3 million value of the shares issued has been adjusted to a fair value of \$37.7 million (see *Note 6. Pro forma adjustments* below). The remaining consideration payable for the acquisition consists of up to \$100 million in cash based on the achievement of certain sales milestones through 2022.

The unaudited pro forma condensed combined balance sheet as of June 30, 2018 gives effect to the proposed acquisitions as if they had occurred on June 30, 2018 and combines the June 30, 2018 historical balance sheet of Emergent with the June 30, 2018 historical balance sheets of PaxVax and Adapt. The unaudited pro forma condensed combined statements of operations are presented as if the proposed acquisitions had occurred on January 1, 2017, and combines the historical results of operations of Emergent for the year ended December 31, 2017 with the historical results of operations of PaxVax and Adapt for the year ended December 31, 2017, and combines the historical results of operations for the six month period ended June 30, 2018 of Emergent with the historical results of operations of PaxVax and Adapt for the six month period ended June 30, 2018. The historical financial information is adjusted to give effect to pro forma events that are (1) directly attributable to the acquisitions, (2) factually supportable and (3) with respect to the statement of operations, expected to have a continuing impact on the combined results of Emergent, PaxVax and Adapt. The unaudited pro forma condensed combined financial statements presented below are based on, and should be read together with, the historical financial statements and accompanying notes of Emergent in its Annual Report on Form 10-K for the year ended December 31, 2017 and its Quarterly Report for the six months ended June 30, 2018 and the historical financial statements and accompanying notes of Adapt, which is incorporated by reference in this amended Form 8-K, along with the historical financial statements and accompanying notes of PaxVax, which are included in this amended Form 8-K.

The unaudited pro forma adjustments related to the acquisitions have been prepared using the acquisition method of accounting and are based on a preliminary purchase price allocation whereby the consideration exchanged to acquire PaxVax and Adapt was allocated to the assets acquired and the liabilities assumed, based upon their estimated fair values. Actual adjustments will be based on analyses of fair values of identifiable tangible and intangible assets, in-process research and development, deferred tax assets and liabilities and estimates of the useful lives of tangible and amortizable intangible assets, which will be completed after Emergent obtains the final third-party valuation, performs its own assessments and reviews all available data. Differences between the preliminary and final purchase price allocations could have a material impact on the unaudited pro forma condensed combined financial statements and Emergent’s future results of operations and financial position.

The unaudited pro forma condensed combined financial statements do not reflect the realization of potential cost savings, or any related restructuring or integration costs that may result from the integration of PaxVax and Adapt. Although Emergent believes that certain cost savings may result from the acquisitions, there can be no assurance that these cost savings will be achieved.

The historical financial statements of Adapt have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”). Emergent has analyzed the financial statements of Adapt and determined the only IFRS to U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) difference is associated with stock-based compensation, which Emergent has removed via a pro forma adjustment (see *Note 6. Pro forma adjustments* below).

The unaudited pro forma condensed combined financial statements are based on estimates and assumptions, are presented for illustrative purposes only and are not necessarily indicative of the condensed combined financial position or results of operations in future periods or the results that actually would have been realized if the proposed acquisitions had been completed as of the dates indicated.

Emergent BioSolutions Inc. and Subsidiaries
Unaudited Pro Forma Condensed Combined Balance Sheet
As of June 30, 2018
(in millions)

	Historical Emergent BioSolutions as of June 30, 2018	Historical PaxVax as of June 30, 2018	Historical Adapt as of June 30, 2018	PaxVax Pro Forma Adjustments	See Note 6	Adapt Pro Forma Adjustments	See Note 6	Emergent Pro Forma Adjustments	See Note 7	Pro Forma Combined
ASSETS										
Current assets:										
Cash and cash equivalents	\$ 190.2	\$ 8.6	\$ 82.8	\$ (279.0) a		\$ (664.3) t		\$ 755.0 uu		\$ 93.3
Restricted cash	1.0	—	—	—		—		—		1.0
Accounts receivable	189.5	7.9	17.7	—		(1.0) u		—		214.1
Inventories, net	139.4	16.6	16.9	5.1 b		20.2 v		—		198.2
Prepaid expenses and other current assets	21.2	3.6	—	—		1.0 u		—		25.8
Total current assets	<u>541.3</u>	<u>36.7</u>	<u>117.4</u>	<u>(273.9)</u>		<u>(644.1)</u>		<u>755.0</u>		<u>532.4</u>
Property, plant and equipment, net	419.2	39.7	0.2	12.3 c		—		—		471.4
Restricted cash	—	72.1	—	(72.1) d		—		—		—
In-process research and development	—	—	—	9.0 e		44.0 w		—		53.0
Intangible assets, net	111.8	2.9	42.9	126.5 f		490.1 x		—		774.2
Goodwill	49.1	—	—	76.6 g		113.3 y		—		239.0
Deferred tax assets, net	12.7	0.9	—	—		—		—		13.6
Other assets	4.8	0.7	3.9	—		2.1 z		—		11.5
Total assets	<u>\$ 1,138.9</u>	<u>\$ 153.0</u>	<u>\$ 164.4</u>	<u>\$ (121.6)</u>		<u>\$ 5.4</u>		<u>755.0</u>		<u>\$ 2,095.1</u>
LIABILITIES AND STOCKHOLDERS' EQUITY										
Current liabilities:										
Accounts payable	\$ 41.6	\$ 5.2	\$ 34.4	\$ —		\$ (24.2) aa		\$ —		\$ 57.0
Accrued expenses and other current liabilities	10.5	15.3	—	(6.4) h		48.4 bb		—		67.8
Accrued compensation	29.3	—	—	6.4 h		—		—		35.7
Contingent purchase consideration, current portion	2.9	—	—	—		—		—		2.9
Long-term indebtedness, current portion	—	—	—	—		—		11.3 vv		11.3
Income tax payable, net	2.8	—	3.5	—		—		—		6.3
Deferred revenue, current portion	9.7	—	—	—		—		—		9.7
Total current liabilities	<u>96.8</u>	<u>20.5</u>	<u>37.9</u>	<u>—</u>		<u>24.2</u>		<u>11.3</u>		<u>190.7</u>
Convertible unsecured loans	—	16.4	—	(16.4) i		—		—		—
Related party convertible notes payable	—	7.1	—	(7.1) i		—		—		—
Long-term indebtedness	13.5	—	—	—		—		743.7 vv		757.2
Contingent purchase consideration, net of current portion	9.8	—	—	—		48.0 cc		—		57.8
Income taxes payable	12.5	—	—	—		—		—		12.5
Pension plan obligation	—	10.7	—	—		—		—		10.7
Deferred revenue, net of current portion	63.3	—	—	—		—		—		63.3
Other liabilities	4.6	0.2	—	—		22.0 dd		—		26.8
Total liabilities	<u>200.5</u>	<u>54.9</u>	<u>37.9</u>	<u>(23.5)</u>		<u>94.2</u>		<u>755.0</u>		<u>1,119.0</u>
Stockholders' equity:										
Preferred stock	—	—	—	—		—		—		—
Common stock	0.1	—	1.2	—		(1.2) ee		—		0.1
Treasury stock	(39.6)	—	—	—		—		—		(39.6)
Additional paid-in capital	632.5	102.3	98.2	(102.3) j		(60.5) ee		—		670.2
Accumulated other comprehensive gain (loss)	(4.4)	(4.2)	—	4.2 j		—		—		(4.4)
Retained earnings	349.8	—	27.1	—		(27.1) ff		—		349.8
Total stockholders' equity	<u>938.4</u>	<u>98.1</u>	<u>126.5</u>	<u>(98.1)</u>		<u>(88.8)</u>		<u>—</u>		<u>976.1</u>
Total liabilities and stockholders' equity	<u>\$ 1,138.9</u>	<u>\$ 153.0</u>	<u>\$ 164.4</u>	<u>\$ (121.6)</u>		<u>\$ 5.4</u>		<u>755.0</u>		<u>\$ 2,095.1</u>

See notes to the Unaudited Pro Forma Condensed Combined Financial Statements

Emergent BioSolutions Inc. and Subsidiaries
Unaudited Pro Forma Condensed Combined Statements of Operations
For the six months ended June 30, 2018
(in millions, except share and per share data)

	Historical Emergent BioSolutions for the six months ended June 30, 2018	Historical PaxVax for the six months ended June 30, 2018	Historical Adapt for the six months ended June 30, 2018	PaxVax Pro Forma Adjustments	See Note 6	Adapt Pro Forma Adjustments	See Note 6	Emergent Pro Forma Adjustments	See Note 7	Pro Forma Combined
Revenues:										
Product sales	\$ 255.8	\$ 21.4	\$ 79.7	\$ —		\$ —		\$ —		\$ 356.9
Contract manufacturing	49.8	—	—	—		—		—		49.8
Contracts and grants	32.4	1.9	—	—		—		—		34.3
Total revenues	338.0	23.3	79.7	—		—		—		441.0
Operating expense:										
Cost of product sales and contract manufacturing	147.2	12.1	30.5	3.5 k		17.7 gg		—		211.0
Research and development	53.8	19.7	3.5	—		—		—		77.0
Selling, general and administrative	79.7	18.7	18.8	0.2 l		(0.8) hh		(1.3) ww		115.3
Income (loss) from operations	57.3	(27.2)	26.9	(3.7)		(16.7)		1.3		37.7
Other income (expense):										
Change in fair value of convertible unsecured loans	—	(4.3)	—	4.3 m		—		—		—
Interest income	0.5	0.7	0.2	—		—		—		1.4
Interest expense	(1.2)	—	—	—		—		(17.0) xx		(18.2)
Other income (expense), net	(0.2)	(0.8)	(0.8)	—		—		—		(1.8)
Total other income (expense)	(0.9)	(4.4)	(0.6)	4.3		—		(17.0)		(18.6)
Income (loss) before provision for (benefit from) income taxes	56.4	(31.6)	26.3	0.6		(16.9)		(15.7)		19.1
Provision for (benefit from) income taxes	11.2	0.4	4.2	0.2 n		(3.6) ii		(3.3) yy		9.1
Net income (loss) from continuing operations	45.2	(32.0)	22.1	0.4		(13.3)		(12.4)		10.0
Net income attributable to noncontrolling interest	—	—	0.8	—		(0.8) jj		—		—
Net income attributable to Emergent, PaxVax and Adapt	\$ 45.2	\$ (32.0)	\$ 22.9	\$ 0.4		\$ (14.1)		\$ (12.4)		\$ 10.0
Net income (loss) from discontinued operations	—	—	(1.5)	—		1.5 kk		—		—
Net income (loss)	\$ 45.2	\$ (32.0)	\$ 21.4	\$ 0.4		\$ (12.6)		\$ (12.4)		\$ 10.0
Earnings per share - basic	\$ 0.91									\$ 0.20
Earnings per share - diluted	\$ 0.89									\$ 0.19
Weighted-average number of shares - basic	49,738,980					733,309 ll				50,472,289
Weighted-average number of shares - diluted	51,039,195					733,309 ll				51,772,504

See notes to the Unaudited Pro Forma Condensed Combined Financial Statements

Emergent BioSolutions Inc. and Subsidiaries
Unaudited Pro Forma Condensed Combined Statements of Operations
For the year ended December 31, 2017
(in millions, except share and per share data)

	Historical Emergent BioSolutions for the year ended December 31, 2017	Historical PaxVax for the year ended December 31, 2017	Historical Adapt for the year ended December 31, 2017	PaxVax Pro Forma Adjustments	See Note 6	Adapt Pro Forma Adjustments	See Note 6	Emergent Pro Forma Adjustments	See Note 7	Pro Forma Combined
Revenues:										
Product sales	\$ 421.5	\$ 35.3	\$ 84.4	\$ —		\$ (0.9) mm		\$ —		\$ 540.3
Contract manufacturing	68.9	—	—	—		—		—		68.9
Contracts and grants	70.4	4.2	—	—		—		—		74.6
Total revenues	560.8	39.5	84.4	—		(0.9)		—		683.8
Operating expense:										
Cost of product sales and contract manufacturing	195.7	19.8	29.2	6.9 o		39.0 nn		—		290.6
Research and development	97.4	31.5	6.9	—		(2.9) oo		—		132.9
Selling, general and administrative	143.5	31.0	30.5	0.5 p		(0.3) pp		—		205.2
Income (loss) from operations	124.2	(42.8)	17.8	(7.4)		(36.7)		—		55.1
Other income (expense):										
Change in fair value of convertible unsecured loans	—	0.6	—	(0.6) q		—		—		—
Gain on extinguishment of royalty obligation	—	0.6	—	(0.6) q		—		—		—
Interest income	1.8	2.0	0.2	—		—		—		4.0
Interest expense	(6.6)	—	—	—		—		(34.1) zz		(40.7)
Other income (expense), net	(0.8)	0.8	1.1	(0.7) r		(0.6) qq		—		(0.2)
Total other income (expense)	(5.6)	4.0	1.3	(1.9)		(0.6)		(34.1)		(36.9)
Income (loss) before provision for (benefit from) income taxes										
	118.6	(38.8)	19.1	(9.3)		(37.3)		(34.1)		18.2
Provision for (benefit from) income taxes	36.0	(0.4)	1.2	(3.2) s		(13.1) rr		(11.9) aaa		8.6
Net income attributable to Emergent, PaxVax and Adapt	82.6	(38.4)	17.9	(6.1)		(24.2)		(22.2)		9.6
Net income attributable to noncontrolling interest	—	—	1.8	—		(1.8) ss		—		—
Net income (loss)	\$ 82.6	\$ (38.4)	\$ 19.7	\$ (6.1)		\$ (26.0)		\$ (22.2)		\$ 9.6
Earnings per share - basic	\$ 1.98									\$ 0.23
Earnings per share - diluted	\$ 1.71									\$ 0.19
Weighted-average number of shares - basic										
	41,816,431					733,309 tt				42,549,740
Weighted-average number of shares - diluted										
	50,327,937					733,309 tt				51,061,246

See notes to the Unaudited Pro Forma Condensed Combined Financial Statements

NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

1. Description of transaction

Acquisition of PaxVax

On October 4, 2018, Emergent completed the acquisition of PaxVax, a company focused on developing, manufacturing, and commercializing specialty vaccines that protect against existing and emerging infectious diseases. At the closing of the transaction, Emergent paid a cash purchase price of \$270.4 million (inclusive of closing adjustments), using a combination of cash-on-hand and borrowings under Emergent's senior secured credit agreement as described in *Note 5. Long-term debt* below.

As part of the acquisition of PaxVax, Emergent acquired the following:

- Vivotif® (Typhoid Vaccine Live Oral Ty21a) ("Vivotif"), the only oral vaccine licensed by the U.S. Food and Drug Administration ("FDA") for the prevention of typhoid fever, a potentially severe and life-threatening infection caused by the bacterium *S. Typhi*. Vivotif is licensed for sale in 27 countries;
- Vaxchora® (Cholera Vaccine Live Oral) ("Vaxchora"), the only FDA-licensed vaccine for the prevention of cholera caused by *Vibrio cholerae* serogroup O1, a potentially serious intestinal disease;
- An adenovirus 4/7 vaccine candidate being developed for military personnel under contract with the U.S. Department of Defense ("DoD") and additional clinical-stage vaccine candidates targeting Chikungunya and other emerging infectious diseases;
- European-based current good manufacturing practices ("cGMP") biologics manufacturing facilities; and
- Approximately 250 employees including those in research and development ("R&D"), manufacturing, and commercial operations with a specialty salesforce in the U.S. and select European countries.

Acquisition of Adapt

On October 15, 2018, Emergent completed the acquisition of Adapt and its NARCAN® (naloxone HCl) Nasal Spray ("NARCAN") marketed product, the first and only needle-free formulation of naloxone approved by the FDA and Health Canada, for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression.

As part of the acquisition of Adapt, Emergent acquired the following:

- NARCAN marketed product;
- A development pipeline of new treatment and delivery options to address opioid overdose; and
- Approximately 50 employees, located in the U.S., Canada, and Ireland, including those responsible for supply chain management, research and development, government affairs, and commercial operations.

Emergent paid \$581.5 million in cash at the closing (inclusive of closing adjustments) and issued 733,309 shares of Common Stock at \$60.44 per share (an aggregate total of \$44.3 million, inclusive of adjustments). The \$44.3 million share value of the shares issued has been adjusted to a fair value of \$37.7 million due to a 2-year share lock-up agreement between Emergent and the Adapt shareholders. The remaining consideration payable for the acquisition consists of up to \$100 million in cash based on the achievement of certain sales milestones through 2022. Emergent funded the cash portion of the payments made at closing using a combination of cash-on-hand and borrowings under its amended and restated senior secured credit agreement as described in *Note 5. Long-term debt* below.

2. Basis of presentation

The unaudited pro forma condensed combined financial statements have been compiled from underlying financial statements of Emergent prepared in accordance with U.S. GAAP and reflects the effects of the acquisitions, prepared using the acquisition method of accounting under existing U.S. GAAP standards.

These transactions will be accounted for by Emergent under the acquisition method of accounting, with Emergent as the acquirer. Under the acquisition method of accounting, the assets and liabilities of PaxVax and Adapt will be recorded as of the acquisition date, at their respective fair values, and combined with those of Emergent. The reported combined financial condition and results of operations of Emergent after completion of the acquisition will reflect these fair values.

The process for estimating the fair values of identifiable intangible assets requires the use of significant estimates and assumptions, including estimating future cash flows and developing appropriate discount rates. The excess of the purchase price over

the estimated fair value of identifiable assets and liabilities of PaxVax and Adapt as of the effective date of the acquisitions will be allocated to goodwill. Fair value is defined, in accordance with U.S. GAAP, as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The preliminary purchase price allocations are subject to finalizing Emergent's analysis of the fair value of PaxVax's and Adapt's assets and liabilities as of the effective dates of the acquisitions and will be adjusted upon completion of the valuations. The use of different estimates could yield materially different results.

These preliminary amounts were determined based upon certain valuations and studies that have yet to be finalized, and accordingly, the assets acquired and liabilities assumed are subject to adjustment once the detailed analyses are completed. These adjustments may be material.

The unaudited pro forma condensed combined balance sheet excludes the tax impacts associated with the assets acquired and liabilities assumed from the acquisitions of PaxVax and Adapt as Emergent has not completed a preliminary assessment of the tax attributes and as such does not have sufficient data to support adjustments as of the date of this filing. Once the tax impacts for the acquisitions have been completed, there could be a material change to the tax asset and liability balances which would cause a corresponding adjustment to goodwill.

The unaudited pro forma condensed combined financial statements are not intended to reflect the financial position or results of operations which would have actually resulted had the acquisition been effected on the dates indicated. Further, the results of operations are not necessarily indicative of the results of operations that may be obtained in the future.

3. Summary of significant accounting policies

The unaudited pro forma condensed combined financial statements have been compiled consistent with Emergent's accounting policies. These accounting policies differ from Adapt's accounting policies, which were prepared in accordance with IFRS.

On January 1, 2018, Emergent adopted Accounting Standards Codification Topic 606, *Revenue from Contracts with Customers* ("ASC 606") utilizing the modified-retrospective method. Emergent has performed a preliminary analysis of the revenue generating contracts from both PaxVax and Adapt and have determined there are no material differences in revenue recognition for the six months ended June 30, 2018.

4. Estimated purchase price

Acquisition of PaxVax

The accompanying unaudited pro forma condensed combined financial statements for PaxVax reflect an estimated purchase price of \$270.4 million in cash.

For purposes of this pro forma analysis, the estimated purchase price for PaxVax has been allocated based on a preliminary estimate of the fair value of assets acquired and liabilities assumed.

(in millions)	June 30, 2018
Estimated fair value of tangible assets acquired and liabilities assumed:	
Acquired tangible assets	\$ 86.8
Assumed tangible liabilities	(31.4)
Total estimated fair value of tangible assets acquired and liabilities assumed	55.4
Identified intangible assets	138.4
Goodwill	76.6
Total preliminary estimated purchase price	<u>\$ 270.4</u>

Acquisition of Adapt

The accompanying unaudited pro forma condensed combined financial statements for Adapt reflect an estimated purchase price as follows:

(in millions)	June 30, 2018
Amount of cash paid to Adapt shareholders	\$ 581.5
Value of Emergent common stock shares issued	37.7
Fair value of contingent purchase consideration	48.0
Total estimated purchase price	<u>\$ 667.2</u>

For purposes of this pro forma analysis, the estimated purchase price for Adapt has been allocated based on a preliminary estimate of the fair value of assets acquired and liabilities assumed.

(in millions)	June 30, 2018
Estimated fair value of tangible assets acquired and liabilities assumed:	
Acquired tangible assets	\$ 61.0
Assumed tangible liabilities	(84.1)
Total estimated fair value of tangible assets acquired and liabilities assumed	(23.1)
Identified intangible assets	577.0
Goodwill	113.8
Total preliminary estimated purchase price	\$ 667.2

5. Long-term debt

On September 29, 2017, Emergent entered into a senior secured credit agreement (the “2017 Credit Agreement”) with four lending financial institutions. The 2017 Credit Agreement provided for a senior secured credit facility of up to \$200 million through September 29, 2022. On October 4, 2018, Emergent drew down \$100 million under the 2017 Credit Agreement to pay for a portion of the purchase of PaxVax.

On October 15, 2018, Emergent entered into an Amended and Restated Credit Agreement, dated as of October 15, 2018 (the “Amended Credit Agreement”), which amended and restated Emergent’s 2017 Credit Agreement, dated as of September 29, 2017.

The Amended Credit Agreement (i) increased the revolving credit facility (the “Revolving Credit Facility”) from \$200 million to \$600 million, (ii) extended the maturity of the Revolving Credit Facility from September 29, 2022 to October 13, 2023, (iii) provided for a term loan in the original principal amount of \$450 million (the “Term Loan Facility”, and together with the Revolving Credit Facility, the “Senior Secured Credit Facility”), (iv) added several additional lenders, (v) amended the applicable margin such that borrowings with respect to the Revolving Credit Facility will bear interest, (vi) amended the provision relating to incremental credit facilities such that Emergent may request one or more incremental term loan facilities, or one or more increases in the commitments under the Revolving Credit Facility (each an “Incremental Loan”), in any amount if, on a pro forma basis, Emergent’s consolidated secured net leverage ratio does not exceed 2.50 to 1.00 after such incurrence, plus \$200 million and (vii) amended the maximum consolidated net leverage ratio financial covenant from 3.50 to 1.0 (subject to 0.50% step up in connection with material acquisitions) to the maximum consolidated net leverage ratio.

Prior to entering into the Amended Credit Agreement, the outstanding principal balance under the 2017 Credit Facility was \$100 million. On October 15, 2018, Emergent borrowed an additional \$218 million, bringing the total borrowings under the Revolving Credit Facility to \$318 million and the full \$450 million under the Term Loan Facility. Such borrowings were used to finance a portion of the consideration for the Adapt acquisition and related fees, costs and expenses and the remainder will be used for general corporate purposes.

6. Pro forma adjustments

PaxVax Adjustments

Adjustments included in the column under the heading “PaxVax Pro Forma Adjustments” are primarily based on the preliminary estimated purchase price valuation and certain adjustments to conform PaxVax’s historical amounts to Emergent’s financial statements presentation. For purposes of these unaudited pro forma condensed combined financial statements, unless as described below the book value of a majority of the tangible assets and liabilities acquired approximates fair value. Further analysis will be performed to confirm these estimates or make adjustments in the final purchase price allocation, as necessary.

The unaudited pro forma condensed combined balance sheet as of June 30, 2018 include adjustments and reclassifications summarized below:

- a. Represents the removal of PaxVax’s cash balance of \$8.6 million as this asset was not included in the acquisition and payment of \$270.4 million to acquire PaxVax.
- b. Reflects the fair value adjustment to step-up inventory to estimated selling price.
- c. Reflects the fair value adjustment to increase the basis in the acquired property, plant and equipment to its fair value.
- d. Elimination of PaxVax’s restricted cash as this asset was not included in the acquisition.
- e. Reflects the fair value of the indefinite-lived intangible assets acquired to be used in research and development activities.
- f. Adjustments to intangible assets, net:

- Reversal of \$2.9 million of intangible assets recorded on PaxVax's historical balance sheet; and
- Fair value adjustment of the intangible assets recorded in purchase accounting. The preliminary identified intangible assets, amortization periods and amortization expense are as follows:

(\$ in millions)	Amount	Amortization Period in years	Pro Forma Amortization Expense for the Year Ended December 31, 2017	Pro Forma Amortization Expense for the Six Months Ended June 30, 2018
Vivotif	\$ 92.0	18	\$ 5.1	\$ 2.6
Vaxchora	37.0	21	1.8	0.9
Partnership relationship	0.4	13	—	—
Total identified intangible assets	<u>\$ 129.4</u>		<u>\$ 6.9</u>	<u>\$ 3.5</u>

The weighted average amortization period for the finite lived identified intangible assets is approximately 19 years.

- g. Adjustment to goodwill representing the estimated purchase price paid in the acquisition in excess of the fair value of the tangible and intangible assets acquired and liabilities assumed.
- h. Reclassify accrued compensation related liabilities to conform with Emergent's balance sheet presentation.
- i. Elimination of PaxVax's convertible unsecured loans and related party convertible notes payable not included in transaction.
- j. Elimination of PaxVax's contributed capital and other comprehensive loss.

The unaudited pro forma condensed combined statement of operations for the six months ended June 30, 2018 includes adjustments and reclassifications summarized below:

- k. To record the inclusion of \$3.5 million of amortization expense during the period for intangible assets recorded in purchase accounting.
- l. Reversal of amortization expense of \$0.1 million recorded by PaxVax during the period for intangible assets; reversal of PaxVax's historical stock compensation expense of \$0.2 million and inclusion of \$0.5 million adjustment for expected stock-based compensation expense under Emergent's 2006 Stock Incentive Plan.
- m. Elimination of fair value adjustments associated with PaxVax's convertible unsecured debt which was not included in the acquisition.
- n. Tax effect of the above six month ended June 30, 2018 PaxVax pro forma adjustments at the U.S. federal statutory rate of 21%.

The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2017 includes adjustments and reclassifications summarized below:

- o. To record the inclusion of \$6.9 million of amortization expense during the period for intangible assets recorded in purchase accounting.
- p. Reversal of amortization expense of \$0.2 million recorded by PaxVax during the period for intangible assets; reversal of PaxVax's historical stock compensation expense of \$0.4 million and inclusion of \$1.1 million adjustment for expected stock-based compensation expense under Emergent's 2006 Stock Incentive Plan.
- q. Elimination of fair value adjustments associated with PaxVax's convertible unsecured debt and the gain on the extinguishment of royalty obligation; which were not included in the acquisition.
- r. Elimination of PaxVax's amortization expense of \$0.7 million related to premiums on investment securities.
- s. Tax effect of the above year ended December 31, 2017 PaxVax pro forma adjustments at the U.S. federal statutory rate of 35%.

Adapt Adjustments

Adjustments included in the column under the heading "Adapt Pro Forma Adjustments" are primarily based on the preliminary estimated purchase price valuation and certain adjustments to conform Adapt's historical amounts to Emergent's financial statements presentation. For purposes of these unaudited pro forma condensed combined financial statements, unless as described below the book value of a majority of the tangible assets and liabilities acquired approximates fair value. Further analysis will be performed to confirm these estimates or make adjustments in the final purchase price allocation, as necessary.

The unaudited pro forma condensed combined balance sheet as of June 30, 2018 include adjustments and reclassifications summarized below:

- t. Represents the removal of Adapt's cash balance of \$82.8 million as this asset was not included in the acquisition and payment of \$581.5 million to acquire Adapt.

- u. Reclassify prepayments and VAT receivables to conform with Emergent's balance sheet presentation.
- v. Reflects the fair value adjustment to step-up inventory to estimated selling price.
- w. Reflects the fair value of the indefinite-lived intangible asset acquired to be used in research and development activities.
- x. Adjustments to finite lived intangible assets, net:
 - Reversal of \$42.9 million of intangible assets recorded on Adapt's historical balance sheet; and
 - Fair value adjustment of the intangible asset recorded in purchase accounting. The preliminary identified intangible assets, amortization periods and amortization expense are as follows:

(\$ in millions)	Amount	Amortization Period in years	Pro Forma Amortization Expense for the Year Ended December 31, 2017	Pro Forma Amortization Expense for the Six Months Ended June 30, 2018
NARCAN	\$ 533.0	13	\$ 41.0	\$ 20.5

- y. Adjustment to goodwill representing the estimated purchase price paid in the acquisition in excess of the fair value of the tangible and intangible assets acquired and liabilities assumed.
- z. Adjustment to reflect an estimated \$6.0 million long-term contract receivable. In addition, the adjustment reflects the removal of \$3.9 million in capacity expansion payments to a third-party as they were subsumed by the NARCAN intangible asset.
- aa. Reclassify accrued sales rebates and returns, milestone payments, royalties and other current accrued liabilities to conform with Emergent's balance sheet presentation.
- bb. Represents \$24.2 liability to Indivior associated with the sale of Adapt to Emergent pursuant to a license agreement.
- cc. Reflects the preliminary fair value of consideration payable to Adapt shareholders of up to \$100 million in cash based on the achievement of certain sales milestones through 2022 and the fair value of a contingent liability to Adapt shareholders.
- dd. Represents the preliminary fair value of sales-based milestones of \$15.0 million and a \$7.0 million liability associated with increased manufacturing capacity.
- ee. Elimination of Adapt's share capital, share premium and share based payment reserve along with the inclusion of \$37.7 million for the 733,309 shares issued to Adapt shareholders as part of the acquisition.
- ff. Elimination of Adapt's retained earnings.

The unaudited pro forma condensed combined statement of operations for the six months ended June 30, 2018 includes adjustments and reclassifications summarized below:

- gg. Reversal of amortization expense of \$2.8 million recorded by Adapt and the inclusion of \$20.5 million of amortization expense during the period for an intangible asset recorded in purchase accounting.
- hh. Reversal of Adapt's historical stock compensation expense, under IFRS, of \$0.3 million and \$0.9 million in transaction cost partially offset by the inclusion of \$0.4 million adjustment for expected stock-based compensation expense under Emergent's 2006 Stock Incentive Plan.
- ii. Tax effect of the above six month ended June 30, 2018 Adapt pro forma adjustments at the U.S federal statutory rate of 21%.
- jj. Reversal of net income attributable to an entity not acquired with the acquisition of Adapt.
- kk. Reversal of discontinued operations from an entity not acquired with the acquisition of Adapt.
- ll. Inclusion of the issuance of 733,309 shares of common stock in conjunction with the acquisition of Adapt.

The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2017 includes adjustments and reclassifications summarized below:

- mm. Reversal of \$0.9 million in revenue from an entity not acquired in the acquisition of Adapt.
- nn. Reversal of \$0.3 million in expense from an entity not acquired in the acquisition of Adapt; reversal of amortization expense of \$1.7 million recorded by Adapt and the inclusion of \$41.0 million of amortization expense during the period for an intangible asset recorded in purchase accounting.
- oo. Reversal of \$2.9 million in expense from an entity not acquired in the acquisition of Adapt.
- pp. Reversal of \$0.7 million in expense from an entity not acquired in the acquisition of Adapt; reversal of Adapt's historical stock compensation expense, under IFRS, of \$0.4 million and inclusion of \$0.8 million adjustment for expected stock compensation expense under Emergent's 2006 Stock Incentive Plan.
- qq. Reversal of \$0.6 million in other income from an entity not acquired in the acquisition of Adapt.
- rr. Tax effect of the above year ended December 31, 2017 Adapt pro forma adjustments at the U.S federal statutory rate of 35%.
- ss. Reversal of net income attributable to an entity not acquired in the acquisition of Adapt.
- tt. Inclusion of the issuance of 733,309 shares of common stock in conjunction with the acquisition of Adapt.

Emergent Adjustments

The unaudited pro forma condensed combined balance sheet as of June 30, 2018 include adjustments summarized below:

- uu. Reflects cash received under the Amended and Restated Credit agreement, net of \$13.0 million debt issuance costs.
- vv. Reflects the current portion of the Term Loan Facility along with the long-term portions of the Term Loan Facility and the Revolving Credit Facility, net of debt issuance costs of \$13.0 million.

The unaudited pro forma condensed combined statement of operations for the six months ended June 30, 2018 includes adjustments and reclassifications summarized below:

- ww. Reversal of Emergent's transaction costs associated with both PaxVax and Adapt of \$1.3 million.
- xx. To record interest expense of \$15.7 million associated with Emergent's debt at an assumed interest rate of 4.097% (based on the 1-month LIBOR rate at November 30, 2018 plus 1.75%) and amortization of deferred financing costs of \$1.3 million for the six months ended June 30, 2018.
- yy. Tax effect of the above six month ended June 30, 2018 Emergent pro forma adjustments at the U.S federal statutory rate of 21%.

The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2017 includes adjustments and reclassifications summarized below:

- zz. To record interest expense of \$31.5 million associated with the Emergent's debt at an assumed interest rate of 4.097% (based on the 1-month LIBOR rate at November 30, 2018 plus 1.75%) and amortization of deferred financing costs of \$2.6 million for the year ended December 31, 2017.
 - aaa. Tax effect of the above year ended December 31, 2017 Emergent pro forma adjustments at the U.S federal statutory rate of 35%.
-